1
|
Steyer A, Puntmann VO, Nagel E, Leistner DM, Koch V, Vasa-Nicotera M, Kumar P, Booz C, Vogl TJ, Mas-Peiro S, Martin SS. Coronary Artery Disease Assessment via On-Site CT Fractional Flow Reserve in Patients Undergoing Transcatheter Aortic Valve Replacement. Radiol Cardiothorac Imaging 2024; 6:e230096. [PMID: 38546330 PMCID: PMC11056750 DOI: 10.1148/ryct.230096] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 01/05/2024] [Accepted: 02/14/2024] [Indexed: 05/01/2024]
Abstract
Purpose To examine the clinical feasibility of workstation-based CT fractional flow reserve (CT-FFR) for coronary artery disease (CAD) evaluation during preprocedural planning in patients undergoing transcatheter aortic valve replacement (TAVR). Materials and Methods In this retrospective single-center study, 434 patients scheduled for TAVR between 2018 and 2020 were screened for study inclusion; a relevant proportion of patients (35.0% [152 of 434]) was not suitable for evaluation due to insufficient imaging properties. A total of 112 patients (mean age, 82.1 years ± 6.7 [SD]; 58 [52%] men) were included in the study. Invasive angiography findings, coronary CT angiography results, and Agatston score were acquired and compared with on-site CT-FFR computation for evaluation of CAD and prediction of major adverse cardiovascular events (MACE) within a 24-month follow-up. Results Hemodynamic relevant CAD, as suggested by CT-FFR of 0.80 or less, was found in 41 of 70 (59%) patients with stenosis of 50% or more. MACE occurred in 23 of 112 (20.5%) patients, from which 14 of 23 had stenoses with CT-FFR of 0.80 or less (hazard ratio [HR], 3.33; 95% CI: 1.56, 7.10; P = .002). CT-FFR remained a significant predictor of MACE after inclusion in a multivariable model with relevant covariables (HR, 2.89; 95% CI: 1.22, 6.86; P = .02). An Agatston score of 1000 Agatston units or more (HR, 2.25; 95% CI: 0.98, 5.21; P = .06) and stenoses of 50% or more determined via invasive angiography (HR, 0.94; 95% CI: 0.41, 2.17; P = .88) were not significant predictors of MACE. Conclusion Compared with conventional CAD markers, CT-FFR better predicted adverse outcomes after TAVR. A relevant portion of the screened cohort, however, was not suitable for CT-based CAD evaluation. Keywords: CT, Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR), Cardiac, Coronary Arteries, Outcomes Analysis © RSNA, 2024 See also the commentary by Weir-McCall and Pugliese in this issue.
Collapse
Affiliation(s)
- Alexandra Steyer
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - Valentina O. Puntmann
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - Eike Nagel
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - David M. Leistner
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - Vitali Koch
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - Mariuca Vasa-Nicotera
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - Parveen Kumar
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - Christian Booz
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | - Thomas J. Vogl
- From the Department of Diagnostic and Interventional Radiology (A.S.,
V.K., C.B., T.J.V., S.S.M.), Institute for Experimental and Translational
Cardiovascular Imaging (A.S., V.O.P., E.N., P.K., S.S.M.), and Department of
Cardiology (D.M.L., M.V.N., S.M.P.), Goethe University Frankfurt, University
Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of
Radiology, Fortis Escort Heart Institute, New Delhi, India (P.K.); German Centre
for Cardiovascular Research, Berlin, Germany (E.N., M.V.N., S.M.P., S.S.M.); and
Cardiopulmonary Institute, Frankfurt, Germany (S.M.P.)
| | | | | |
Collapse
|
2
|
Shumliakivska M, Luxán G, Hemmerling I, Scheller M, Li X, Müller-Tidow C, Schuhmacher B, Sun Z, Dendorfer A, Debes A, Glaser SF, Muhly-Reinholz M, Kirschbaum K, Hoffmann J, Nagel E, Puntmann VO, Cremer S, Leuschner F, Abplanalp WT, John D, Zeiher AM, Dimmeler S. DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts. Nat Commun 2024; 15:606. [PMID: 38242884 PMCID: PMC10799021 DOI: 10.1038/s41467-023-43003-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 10/27/2023] [Indexed: 01/21/2024] Open
Abstract
Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined transcriptomic data derived from peripheral blood mononuclear cells of HF patients, both with and without CHIP, and cardiac tissue. We demonstrate that inactivation of DNMT3A in macrophages intensifies interactions with cardiac fibroblasts and increases cardiac fibrosis. DNMT3A inactivation amplifies the release of heparin-binding epidermal growth factor-like growth factor, thereby facilitating activation of cardiac fibroblasts. These findings identify a potential pathway of DNMT3A CHIP-driver mutations to the initiation and progression of HF and may also provide a compelling basis for the development of innovative anti-fibrotic strategies.
Collapse
Affiliation(s)
- Mariana Shumliakivska
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany
| | - Guillermo Luxán
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany
| | - Inga Hemmerling
- Department of Internal Medicine III, University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120, Heidelberg, Germany
| | - Marina Scheller
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
| | - Xue Li
- Department of Internal Medicine III, University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120, Heidelberg, Germany
| | - Carsten Müller-Tidow
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
| | - Bianca Schuhmacher
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Zhengwu Sun
- Walter-Brendel-Centre of Experimental Medicine, Hospital of the Ludwig-Maximilians-University Munich, Marchioninistraße 68, 81377, München, Germany
| | - Andreas Dendorfer
- Walter-Brendel-Centre of Experimental Medicine, Hospital of the Ludwig-Maximilians-University Munich, Marchioninistraße 68, 81377, München, Germany
| | - Alisa Debes
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Simone-Franziska Glaser
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany
| | - Marion Muhly-Reinholz
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Klara Kirschbaum
- Department of Medicine, Cardiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Jedrzej Hoffmann
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Institute of Experimental and Translational Cardiovascular Imaging, Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Eike Nagel
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Institute of Experimental and Translational Cardiovascular Imaging, Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Institute of Experimental and Translational Cardiovascular Imaging, Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Sebastian Cremer
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany
- Department of Medicine, Cardiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Florian Leuschner
- Department of Internal Medicine III, University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120, Heidelberg, Germany
| | - Wesley Tyler Abplanalp
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany
| | - David John
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany
| | - Andreas M Zeiher
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany
| | - Stefanie Dimmeler
- Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
- German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
- Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.
| |
Collapse
|
3
|
Kattih B, Boeckling F, Shumliakivska M, Tombor L, Rasper T, Schmitz K, Hoffmann J, Nicin L, Abplanalp WT, Carstens DC, Arsalan M, Emrich F, Holubec T, Walther T, Puntmann VO, Nagel E, John D, Zeiher AM, Dimmeler S. Single-nuclear transcriptome profiling identifies persistent fibroblast activation in hypertrophic and failing human hearts of patients with longstanding disease. Cardiovasc Res 2023; 119:2550-2562. [PMID: 37648651 DOI: 10.1093/cvr/cvad140] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 06/08/2023] [Accepted: 06/24/2023] [Indexed: 09/01/2023] Open
Abstract
AIMS Cardiac fibrosis drives the progression of heart failure in ischaemic and hypertrophic cardiomyopathy. Therefore, the development of specific anti-fibrotic treatment regimens to counteract cardiac fibrosis is of high clinical relevance. Hence, this study examined the presence of persistent fibroblast activation during longstanding human heart disease at a single-cell resolution to identify putative therapeutic targets to counteract pathological cardiac fibrosis in patients. METHODS AND RESULTS We used single-nuclei RNA sequencing with human tissues from two samples of one healthy donor, and five hypertrophic and two failing hearts. Unsupervised sub-clustering of 7110 nuclei led to the identification of 7 distinct fibroblast clusters. De-convolution of cardiac fibroblast heterogeneity revealed a distinct population of human cardiac fibroblasts with a molecular signature of persistent fibroblast activation and a transcriptional switch towards a pro-fibrotic extra-cellular matrix composition in patients with established cardiac hypertrophy and heart failure. This sub-cluster was characterized by high expression of POSTN, RUNX1, CILP, and a target gene adipocyte enhancer-binding protein 1 (AEBP1) (all P < 0.001). Strikingly, elevated circulating AEBP1 blood level were also detected in a validation cohort of patients with confirmed cardiac fibrosis and hypertrophic cardiomyopathy by cardiac magnetic resonance imaging (P < 0.01). Since endogenous AEBP1 expression was increased in patients with established cardiac hypertrophy and heart failure, we assessed the functional consequence of siRNA-mediated AEBP1 silencing in human cardiac fibroblasts. Indeed, AEBP1 silencing reduced proliferation, migration, and fibroblast contractile capacity and α-SMA gene expression, which is a hallmark of fibroblast activation (all P < 0.05). Mechanistically, the anti-fibrotic effects of AEBP1 silencing were linked to transforming growth factor-beta pathway modulation. CONCLUSION Together, this study identifies persistent fibroblast activation in patients with longstanding heart disease, which might be detected by circulating AEBP1 and therapeutically modulated by its targeted silencing in human cardiac fibroblasts.
Collapse
Affiliation(s)
- Badder Kattih
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- Goethe University Frankfurt, University Hospital, Department of Cardiology, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| | - Felicitas Boeckling
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- Goethe University Frankfurt, University Hospital, Department of Cardiology, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| | - Mariana Shumliakivska
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| | - Lukas Tombor
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Tina Rasper
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Katja Schmitz
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| | - Jedrzej Hoffmann
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
- Goethe University Frankfurt, University Hospital, Centre for Cardiovascular Imaging, Institute of Experimental and Translational Cardiovascular Imaging, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Luka Nicin
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Wesley T Abplanalp
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Daniel C Carstens
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| | - Mani Arsalan
- Goethe University Frankfurt, University Hospital, Department of Cardiovascular Surgery, Theodor-Stern-Kai 7, Frankfurt 60590, Germany
| | - Fabian Emrich
- Goethe University Frankfurt, University Hospital, Department of Cardiovascular Surgery, Theodor-Stern-Kai 7, Frankfurt 60590, Germany
| | - Tomas Holubec
- Goethe University Frankfurt, University Hospital, Department of Cardiovascular Surgery, Theodor-Stern-Kai 7, Frankfurt 60590, Germany
| | - Thomas Walther
- Goethe University Frankfurt, University Hospital, Department of Cardiovascular Surgery, Theodor-Stern-Kai 7, Frankfurt 60590, Germany
| | - Valentina O Puntmann
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
- Goethe University Frankfurt, University Hospital, Centre for Cardiovascular Imaging, Institute of Experimental and Translational Cardiovascular Imaging, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Eike Nagel
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
- Goethe University Frankfurt, University Hospital, Centre for Cardiovascular Imaging, Institute of Experimental and Translational Cardiovascular Imaging, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - David John
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| | - Andreas M Zeiher
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| | - Stefanie Dimmeler
- Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- German Centre for Cardiovascular Research, Partner Site Rhine-Main, 60590 Frankfurt am Main, Germany
| |
Collapse
|
4
|
Puntmann VO, Shchendrygina A, Bolanos CR, Madjiguène Ka M, Valbuena S, Rolf A, Escher F, Nagel E. Cardiac Involvement Due to COVID-19: Insights from Imaging and Histopathology. Eur Cardiol 2023; 18:e58. [PMID: 37942208 PMCID: PMC10628999 DOI: 10.15420/ecr.2023.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Accepted: 07/04/2023] [Indexed: 11/10/2023] Open
Abstract
Lingering cardiac symptoms are increasingly recognised complications of severe acute respiratory syndrome coronavirus 2 infection, now referred to as post-acute cardiovascular sequelae of COVID-19 (PASC). In the acute phase, cardiac injury is driven by cytokine release and stems from ischaemic and thrombotic complications, resulting in myocardial necrosis. Patients with pre-existing cardiac conditions are particularly vulnerable. Myocarditis due to a direct viral infection is rare. Chronic symptoms relate to either worsening of pre-existing heart disease (PASC - cardiovascular disease) or delayed chronic inflammatory condition due to heterogenous immune dysregulation (PASC - cardiovascular syndrome), the latter affecting a broad segment of previously well people. Both PASC presentations are associated with increased cardiovascular risk, long-term disability and reduced quality of life. The recognition and management of PASC in clinical settings remains a considerable challenge. Sensitive diagnostic methods are needed to detect subtler inflammatory changes that underlie the persistent symptoms in PASC - cardiovascular syndrome, alongside considerable clinical experience in inflammatory cardiac conditions.
Collapse
Affiliation(s)
- Valentina O Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt Frankfurt am Main, Germany
| | - Anastasia Shchendrygina
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt Frankfurt am Main, Germany
| | - Carlos Rodriguez Bolanos
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt Frankfurt am Main, Germany
| | - Mame Madjiguène Ka
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt Frankfurt am Main, Germany
| | - Silvia Valbuena
- Department of Cardiology, University Hospital La Paz Madrid, Spain
| | - Andreas Rolf
- Department of Cardiology, Campus Kerckhoff of Justus-Liebig-University Giessen Bad Nauheim, Germany
| | - Felicitas Escher
- Institute of Cardiac Diagnostics and Therapy, IKDT GmbH Berlin, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt Frankfurt am Main, Germany
| |
Collapse
|
5
|
Steyer A, Mas-Peiro S, Leistner DM, Puntmann VO, Nagel E, Dey D, Goeller M, Koch V, Booz C, Vogl TJ, Martin SS. Computed tomography-based pericoronary adipose tissue attenuation in patients undergoing TAVR: a novel method for risk assessment. Front Cardiovasc Med 2023; 10:1192093. [PMID: 37288259 PMCID: PMC10242002 DOI: 10.3389/fcvm.2023.1192093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 04/27/2023] [Indexed: 06/09/2023] Open
Abstract
Objectives This study aims to assess the attenuation of pericoronary adipose tissue (PCAT) surrounding the proximal right coronary artery (RCA) in patients with aortic stenosis (AS) and undergoing transcatheter aortic valve replacement (TAVR). RCA PCAT attenuation is a novel computed tomography (CT)-based marker for evaluating coronary inflammation. Coronary artery disease (CAD) in TAVR patients is common and usually evaluated prior to intervention. The most sensible screening method and consequential treatment approach are unclear and remain a matter of ceaseless discussion. Thus, interest remains for safe and low-demand predictive markers to identify patients at risk for adverse outcomes postaortic valve replacement. Methods This single-center retrospective study included patients receiving a standard planning CT scan prior to TAVR. Conventional CAD diagnostic tools, such as coronary artery calcium score and significant stenosis via invasive coronary angiography and coronary computed tomography angiography, were determined in addition to RCA PCAT attenuation using semiautomated software. These were assessed for their relationship with major adverse cardiovascular events (MACE) during a 24-month follow-up period. Results From a total of 62 patients (mean age: 82 ± 6.7 years), 15 (24.2%) patients experienced an event within the observation period, 10 of which were attributed to cardiovascular death. The mean RCA PCAT attenuation was higher in patients enduring MACE than that in those without an endpoint (-69.8 ± 7.5 vs. -74.6 ± 6.2, P = 0.02). Using a predefined cutoff of >-70.5 HU, 20 patients (32.3%) with high RCA PCAT attenuation were identified, nine (45%) of which met the endpoint within 2 years after TAVR. In a multivariate Cox regression model including conventional CAD diagnostic tools, RCA PCAT attenuation prevailed as the only marker with significant association with MACE (P = 0.02). After dichotomization of patients into high- and low-RCA PCAT attenuation groups, high attenuation was related to greater risk of MACE (hazard ration: 3.82, P = 0.011). Conclusion RCA PCAT attenuation appears to have predictive value also in a setting of concomitant AS in patients receiving TAVR. RCA PCAT attenuation was more reliable than conventional CAD diagnostic tools in identifying patients at risk for MACE .
Collapse
Affiliation(s)
- Alexandra Steyer
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt, Germany
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - Silvia Mas-Peiro
- Department of Cardiology, University Hospital Frankfurt, Frankfurt, Germany
- German Centre for Cardiovascular Research (DZHK), Berlin, Germany
- Cardiopulmonary Institute (CPI), Frankfurt am Main, Germany
| | - David M. Leistner
- Department of Cardiology, University Hospital Frankfurt, Frankfurt, Germany
| | - Valentina O. Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
- German Centre for Cardiovascular Research (DZHK), Berlin, Germany
| | - Damini Dey
- Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States
| | - Markus Goeller
- Department of Cardiology, Friedrich-Alexander-University Hospital Erlangen, Erlangen, Germany
| | - Vitali Koch
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt, Germany
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - Christian Booz
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt, Germany
| | - Thomas J. Vogl
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt, Germany
| | - Simon S. Martin
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt, Germany
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
6
|
Valbuena-López SC, Camastra G, Cacciotti L, Nagel E, Puntmann VO, Arcari L. Cardiac Imaging Biomarkers in Chronic Kidney Disease. Biomolecules 2023; 13:biom13050773. [PMID: 37238643 DOI: 10.3390/biom13050773] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 04/24/2023] [Accepted: 04/27/2023] [Indexed: 05/28/2023] Open
Abstract
Uremic cardiomyopathy (UC), the peculiar cardiac remodeling secondary to the systemic effects of renal dysfunction, is characterized by left ventricular (LV) diffuse fibrosis with hypertrophy (LVH) and stiffness and the development of heart failure and increased rates of cardiovascular mortality. Several imaging modalities can be used to obtain a non-invasive assessment of UC by different imaging biomarkers, which is the focus of the present review. Echocardiography has been largely employed in recent decades, especially for the determination of LVH by 2-dimensional imaging and diastolic dysfunction by pulsed-wave and tissue Doppler, where it retains a robust prognostic value; more recent techniques include parametric assessment of cardiac deformation by speckle tracking echocardiography and the use of 3D-imaging. Cardiac magnetic resonance (CMR) imaging allows a more accurate assessment of cardiac dimensions, including the right heart, and deformation by feature-tracking imaging; however, the most evident added value of CMR remains tissue characterization. T1 mapping demonstrated diffuse fibrosis in CKD patients, increasing with the worsening of renal disease and evident even in early stages of the disease, with few, but emerging, prognostic data. Some studies using T2 mapping highlighted the presence of subtle, diffuse myocardial edema. Finally, computed tomography, though rarely used to specifically assess UC, might provide incidental findings carrying prognostic relevance, including information on cardiac and vascular calcification. In summary, non-invasive cardiovascular imaging provides a wealth of imaging biomarkers for the characterization and risk-stratification of UC; integrating results from different imaging techniques can aid a better understanding of the physiopathology of UC and improve the clinical management of patients with CKD.
Collapse
Affiliation(s)
| | - Giovanni Camastra
- Cardiology Unit, Madre Giuseppina Vannini Hospital, 00177 Rome, Italy
| | - Luca Cacciotti
- Cardiology Unit, Madre Giuseppina Vannini Hospital, 00177 Rome, Italy
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Luca Arcari
- Cardiology Unit, Madre Giuseppina Vannini Hospital, 00177 Rome, Italy
| |
Collapse
|
7
|
Puntmann VO, Valbuena-López S. ESC Congress 2022 Imaging Highlights. Eur Cardiol 2023. [DOI: 10.15420/ecr.2022.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023] Open
Abstract
Cardiac imaging is an ever-evolving area, with imaging parameters and application in constant re-evaluation. This was reflected in many imaging debates and by the increased number of scientific contributions at the European Society of Cardiology Congress in 2022. While clinical trials tried to answer clinical questions related to the performance of different imaging modalities, many high-quality presentations focused on new imaging biomarkers in different scenarios, such as heart failure with preserved ejection fraction, valvular heart disease or long COVID. This highlights the need for the translation of cardiac imaging technology from research interests towards established measures of clinical practice.
Collapse
Affiliation(s)
- Valentina O Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt , Frankfurt, Germany
| | | |
Collapse
|
8
|
Koch V, Martin SS, Gruber-Rouh T, Eichler K, Mahmoudi S, Leistner DM, Scholtz JE, Bernatz S, Puntmann VO, Nagel E, Booz C, D'Angelo T, Alizadeh LS, Yel I, Ziegengeist NS, Torgashov K, Geyer T, Hardt SE, Vogl TJ, Gruenewald LD, Giannitsis E. Cancer patients with venous thromboembolism: Diagnostic and prognostic value of elevated D-dimers. Eur J Clin Invest 2023; 53:e13914. [PMID: 36444723 DOI: 10.1111/eci.13914] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 11/22/2022] [Accepted: 11/23/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND D-dimer testing is known to have a high sensitivity at simultaneously low specificity, resulting in nonspecific elevations in a variety of conditions. METHODS This retrospective study sought to assess diagnostic and prognostic features of D-dimers in cancer patients referred to the emergency department for suspected pulmonary embolism (PE) and deep vein thrombosis (DVT). In total, 526 patients with a final adjudicated diagnosis of PE (n = 83) and DVT (n = 69) were enrolled, whereas 374 patients served as the comparative group, in which venous thromboembolism (VTE) has been excluded. RESULTS For the identification of VTE, D-dimers yielded the highest positive predictive value of 96% (95% confidence interval (CI), 85-99) at concentrations of 9.9 mg/L and a negative predictive value of 100% at .6 mg/L (95% CI, 97-100). At the established rule-out cut-off level of .5 mg/L, D-dimers were found to be very sensitive (100%) at a moderate specificity of nearly 65%. Using an optimised cut-off value of 4.9 mg/L increased the specificity to 95% for the detection of life-threatening VTE at the cost of moderate sensitivities (64%). During a median follow-up of 30 months, D-dimers positively correlated with the reoccurrence of VTE (p = .0299) and mortality in both cancer patients with VTE (p < .0001) and without VTE (p = .0008). CONCLUSIONS Although D-dimer testing in cancer patients is discouraged by current guidelines, very high concentrations above the 10-fold upper reference limit contain diagnostic and prognostic information and might be helpful in risk assessment, while low concentrations remain useful for ruling out VTE.
Collapse
Affiliation(s)
- Vitali Koch
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany
| | - Simon S Martin
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Katrin Eichler
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - David M Leistner
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Jan-Erik Scholtz
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Simon Bernatz
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Eike Nagel
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Christian Booz
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Tommaso D'Angelo
- Department of Biomedical Sciences and Morphological and Functional Imaging, University Hospital Messina, Messina, Italy
| | - Leona S Alizadeh
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Ibrahim Yel
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | | | - Tobias Geyer
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Stefan E Hardt
- Department of Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany
| | - Thomas J Vogl
- Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Evangelos Giannitsis
- Department of Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany
| |
Collapse
|
9
|
Vanchin B, Ka MM, Arendt CT, Escher F, Nagel E, Puntmann VO. Myocardial tissue changes detected by cardiac MRI in a patient with suspected systemic sarcoidosis. BMC Cardiovasc Disord 2023; 23:131. [PMID: 36906545 PMCID: PMC10007775 DOI: 10.1186/s12872-023-03133-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 02/19/2023] [Indexed: 03/13/2023] Open
Abstract
BACKGROUND The role of cardiac magnetic resonance imaging in the early management of chronic cardiac inflammatory conditions is growing. Our case enlightens the benefit of quantitative mapping in the monitoring and treatment guidance in systemic sarcoidosis. CASE PRESENTATION We report about a 29-year-old man with an ongoing dyspnea and bihilar lymphadenopathy, suggesting sarcoidosis. Cardiac magnetic resonance showed high mapping values, but no scarring. In follow-ups, cardiac remodeling was noted; cardioprotective treatment normalized cardiac function and mapping markers. Definitive diagnosis was achieved in extracardiac lymphatic tissue during a relapse. CONCLUSION This case shows the role that mapping markers can play in the detection and treatment at early stage of systemic sarcoidosis.
Collapse
Affiliation(s)
- Byambasuren Vanchin
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt Am Main, Germany.,Department of Cardiology, School of Medicine, Mongolia-Japan Teaching Hospital, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
| | - Mame Madjiguène Ka
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt Am Main, Germany.
| | - Christophe T Arendt
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt Am Main, Germany
| | - Felicitas Escher
- Department of Cardiology, University Hospital Berlin Charite, Berlin, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt Am Main, Germany
| | - Valentina O Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt Am Main, Germany
| |
Collapse
|
10
|
Treiber J, Hausmann CS, Wolter JS, Fischer-Rasokat U, Kriechbaum SD, Hamm CW, Nagel E, Puntmann VO, Rolf A. Native T1 is predictive of cardiovascular death/heart failure events and all-cause mortality irrespective of the patient's volume status. Front Cardiovasc Med 2023; 10:1091334. [PMID: 36865890 PMCID: PMC9971619 DOI: 10.3389/fcvm.2023.1091334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Accepted: 01/19/2023] [Indexed: 02/16/2023] Open
Abstract
Background Native T1 has become a pivotal parameter of tissue composition that is assessed by cardiac magnetic resonance (CMR). It characterizes diseased myocardium and can be used for prognosis estimation. Recent publications have shown that native T1 is influenced by short-term fluctuations of volume status due to hydration or hemodialysis. Methods Patients from a prospective BioCVI all-comers clinical CMR registry were included, and native T1 and plasma volume status (PVS) were determined according to Hakim's formula as surrogate markers of patient volume status. The primary endpoint was defined as combined endpoint of cardiovascular death or hospitalization for heart failure events, the secondary endpoint was defined as all-cause mortality. Results A total of 2,047 patients were included since April 2017 [median (IQR); age 63 (52-72) years, 33% female]. There was a significant although weak influence of PVS on native T1 (β = 0.11, p < 0.0001). Patients with volume expansion (PVS > -13%) showed significantly higher values for tissue markers than non-volume-overloaded patients [PVS ≤ -13%; median (IQR); native T1 1,130 (1,095-1,170) vs. 1,123 (1,086-1,166) ms, p < 0.003; and T2 39 (37-40) vs. 38 (36-40) ms, p < 0.0001]. In Cox regression analysis both native T1 and PVS were independently predictive of the primary endpoint and all-cause mortality. Conclusion Despite a weak effect of PVS on native T1, its predictive power was not affected in a large, all-comers cohort.
Collapse
Affiliation(s)
- Julia Treiber
- Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany,German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany
| | - Carla S. Hausmann
- Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany,German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany
| | - Jan Sebastian Wolter
- Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany,German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany
| | - Ulrich Fischer-Rasokat
- Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany,German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany
| | - Steffen D. Kriechbaum
- Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany,German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany
| | - Christian W. Hamm
- Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany,German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany,Justus Liebig University of Giessen, Giessen, Germany
| | - Eike Nagel
- German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany,Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt am Main, Frankfurt, Germany
| | - Valentina O. Puntmann
- German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany,Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt am Main, Frankfurt, Germany
| | - Andreas Rolf
- Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany,German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany,Justus Liebig University of Giessen, Giessen, Germany,*Correspondence: Andreas Rolf, ✉
| |
Collapse
|
11
|
Kumar P, Arendt C, Martin S, Al Soufi S, DeLeuw P, Nagel E, Puntmann VO. Multimodality Imaging in HIV-Associated Cardiovascular Complications: A Comprehensive Review. Int J Environ Res Public Health 2023; 20:2201. [PMID: 36767567 PMCID: PMC9915416 DOI: 10.3390/ijerph20032201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 01/17/2023] [Accepted: 01/20/2023] [Indexed: 06/18/2023]
Abstract
Human immunodeficiency virus (HIV) infection is a leading cause of mortality and morbidity worldwide. The introduction of antiretroviral therapy (ART) has significantly reduced the risk of developing acquired immune deficiency syndrome and increased life expectancy, approaching that of the general population. However, people living with HIV have a substantially increased risk of cardiovascular diseases despite long-term viral suppression using ART. HIV-associated cardiovascular complications encompass a broad spectrum of diseases that involve the myocardium, pericardium, coronary arteries, valves, and systemic and pulmonary vasculature. Traditional risk stratification tools do not accurately predict cardiovascular risk in this population. Multimodality imaging plays an essential role in the evaluation of various HIV-related cardiovascular complications. Here, we emphasize the role of multimodality imaging in establishing the diagnosis and aetiopathogenesis of various cardiovascular manifestations related to chronic HIV disease. This review also provides a critical appraisal of contemporary data and illustrative cases.
Collapse
Affiliation(s)
- Parveen Kumar
- Institute of Experimental and Translational Cardiac Imaging, DZHK, Centre for Cardiovascular Imaging, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
| | - Christophe Arendt
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
| | - Simon Martin
- Institute of Experimental and Translational Cardiac Imaging, DZHK, Centre for Cardiovascular Imaging, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
| | - Safaa Al Soufi
- Institute of Experimental and Translational Cardiac Imaging, DZHK, Centre for Cardiovascular Imaging, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
| | | | - Eike Nagel
- Institute of Experimental and Translational Cardiac Imaging, DZHK, Centre for Cardiovascular Imaging, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
| | - Valentina O. Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK, Centre for Cardiovascular Imaging, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
| |
Collapse
|
12
|
Puntmann VO, Martin S, Shchendrygina A, Hoffmann J, Ka MM, Giokoglu E, Vanchin B, Holm N, Karyou A, Laux GS, Arendt C, De Leuw P, Zacharowski K, Khodamoradi Y, Vehreschild MJGT, Rohde G, Zeiher AM, Vogl TJ, Schwenke C, Nagel E. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med 2022; 28:2117-2123. [PMID: 36064600 PMCID: PMC9556300 DOI: 10.1038/s41591-022-02000-0] [Citation(s) in RCA: 48] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 08/08/2022] [Indexed: 01/03/2023]
Abstract
Cardiac symptoms are increasingly recognized as late complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in previously well individuals with mild initial illness, but the underlying pathophysiology leading to long-term cardiac symptoms remains unclear. In this study, we conducted serial cardiac assessments in a selected population of individuals with Coronavirus Disease 2019 (COVID-19) with no previous cardiac disease or notable comorbidities by measuring blood biomarkers of heart injury or dysfunction and by performing magnetic resonance imaging. Baseline measurements from 346 individuals with COVID-19 (52% females) were obtained at a median of 109 days (interquartile range (IQR), 77-177 days) after infection, when 73% of participants reported cardiac symptoms, such as exertional dyspnea (62%), palpitations (28%), atypical chest pain (27%) and syncope (3%). Symptomatic individuals had higher heart rates and higher imaging values or contrast agent accumulation, denoting inflammatory cardiac involvement, compared to asymptomatic individuals. Structural heart disease or high levels of biomarkers of cardiac injury or dysfunction were rare in symptomatic individuals. At follow-up (329 days (IQR, 274-383 days) after infection), 57% of participants had persistent cardiac symptoms. Diffuse myocardial edema was more pronounced in participants who remained symptomatic at follow-up as compared to those who improved. Female gender and diffuse myocardial involvement on baseline imaging independently predicted the presence of cardiac symptoms at follow-up. Ongoing inflammatory cardiac involvement may, at least in part, explain the lingering cardiac symptoms in previously well individuals with mild initial COVID-19 illness.
Collapse
Affiliation(s)
- Valentina O Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.
| | - Simon Martin
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Anastasia Shchendrygina
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Jedrzej Hoffmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.,Institute of Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Mame Madjiguène Ka
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Eleni Giokoglu
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Byambasuren Vanchin
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Niels Holm
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Argyro Karyou
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Gerald S Laux
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Christophe Arendt
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Kai Zacharowski
- Department of Anesthesiology, Intensive Care Medicine & Pain Therapy; Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Yascha Khodamoradi
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Maria J G T Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Gernot Rohde
- Department of Internal Medicine, Respiratory Medicine, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Andreas M Zeiher
- Institute of Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Thomas J Vogl
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
13
|
Gluckman TJ, Bhave NM, Allen LA, Chung EH, Spatz ES, Ammirati E, Baggish AL, Bozkurt B, Cornwell WK, Harmon KG, Kim JH, Lala A, Levine BD, Martinez MW, Onuma O, Phelan D, Puntmann VO, Rajpal S, Taub PR, Verma AK. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play. J Am Coll Cardiol 2022; 79:1717-1756. [PMID: 35307156 PMCID: PMC8926109 DOI: 10.1016/j.jacc.2022.02.003] [Citation(s) in RCA: 171] [Impact Index Per Article: 85.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
14
|
Arcari L, Engel J, Freiwald T, Zhou H, Zainal H, Gawor M, Buettner S, Geiger H, Hauser I, Nagel E, Puntmann VO. Cardiac biomarkers in chronic kidney disease are independently associated with myocardial edema and diffuse fibrosis by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2021; 23:71. [PMID: 34092229 PMCID: PMC8183054 DOI: 10.1186/s12968-021-00762-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Accepted: 04/28/2021] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND High sensitivity cardiac troponin T (hs-cTnT) and NT-pro-brain natriuretic peptide (NT-pro BNP) are often elevated in chronic kidney disease (CKD) and associated with both cardiovascular remodeling and outcome. Relationship between these biomarkers and quantitative imaging measures of myocardial fibrosis and edema by T1 and T2 mapping remains unknown. METHODS Consecutive patients with established CKD and estimated glomerular filtration rate (eGFR) < 59 ml/min/1.73 m2 (n = 276) were compared to age/sex matched patients with eGFR ≥ 60 ml/min/1.73 m2 (n = 242) and healthy controls (n = 38). Comprehensive cardiovascular magnetic resonance (CMR) with native T1 and T2 mapping, myocardial ischemia and scar imaging was performed with venous sampling immediately prior to CMR. RESULTS Patients with CKD showed significant cardiac remodeling in comparison with both healthy individuals and non-CKD patients, including a stepwise increase of native T1 and T2 (p < 0.001 between all CKD stages). Native T1 and T2 were the sole imaging markers independently associated with worsening CKD in patients [B = 0.125 (95% CI 0.022-0.235) and B = 0.272 (95% CI 0.164-0.374) with p = 0.019 and < 0.001 respectively]. At univariable analysis, both hs-cTnT and NT-pro BNP significantly correlated with native T1 and T2 in groups with eGFR 30-59 ml/min/1.73 m2 and eGFR < 29 ml/min/1.73 m2 groups, with associations being stronger at lower eGFR (NT-pro BNP (log transformed, lg10): native T1 r = 0.43 and r = 0.57, native T2 r = 0.39 and r = 0.48 respectively; log-transformed hs-cTnT(lg10): native T1 r = 0.23 and r = 0.43, native T2 r = 0.38 and r = 0.58 respectively, p < 0.001 for all, p < 0.05 for interaction). On multivariable analyses, we found independent associations of native T1 with NT-pro BNP [(B = 0.308 (95% CI 0.129-0.407), p < 0.001 and B = 0.334 (95% CI 0.154-0.660), p = 0.002 for eGFR 30-59 ml/min/1.73 m2 and eGFR < 29 ml/min/1.73 m2, respectively] and of T2 with hs-cTnT [B = 0.417 (95% CI 0.219-0.650), p < 0.001 for eGFR < 29 ml/min/1.73 m2]. CONCLUSIONS We demonstrate independent associations between cardiac biomarkers with imaging markers of interstitial expansion, which are CKD-group specific. Our findings indicate the role of diffuse non-ischemic tissue processes, including excess of myocardial fluid in addition to diffuse fibrosis in CKD-related adverse remodeling.
Collapse
Affiliation(s)
- Luca Arcari
- Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
- Cardiology Unit, Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
| | - Juergen Engel
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Tilo Freiwald
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Hui Zhou
- Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
- Department of Radiology, XiangYa Hospital, Central South University, Changsha, Hunan, China
| | - Hafisyatul Zainal
- Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
- Department of Cardiology, Universiti Teknologi MARA (UiTM), Sg. Buloh, Malaysia
| | - Monika Gawor
- Department of Cardiology, University Hospital Warsaw, Warsaw, Poland
| | - Stefan Buettner
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Helmut Geiger
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Ingeborg Hauser
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
| |
Collapse
|
15
|
Grigoratos C, Gueli I, Arendt CT, Leithner D, Meloni A, Nugara C, Barison A, Todiere G, Puntmann VO, Novo G, Pepe A, Emdin M, Nagel E, Aquaro GD. Prevalence and prognostic impact of nonischemic late gadolinium enhancement in stress cardiac magnetic resonance. J Cardiovasc Med (Hagerstown) 2021; 21:980-985. [PMID: 33156590 DOI: 10.2459/jcm.0000000000001016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
AIM To assess the prevalence and prognostic significance of NI-LGE in patients undergoing stress-CMR. METHODS Stress-CMR with either dipyridamole or adenosine was performed in 283 patients (228 men, 81%) including perfusion imaging, wall motion evaluation and LGE. Follow-up was completed in all enrolled patients (median time: 1850 days; interquartile range: 1225-2705 days). Composite endpoint included cardiac death, ventricular tachycardia, myocardial infarction, stroke, hospitalization for cardiac cause and coronary revascularization performed beyond 90 days from stress-CMR scans. RESULTS One hundred and twelve patients (40%) had negative LGE (no-LGE), 140 patients (49%) I-LGE and 31 patients (11%) NI-LGE. Twenty-five events occurred in the no-LGE group, 68 in I-LGE and 11 in the NI-LGE group. On survival curves, patients with NI-LGE had worse prognosis than patients with no-LGE regardless of the presence of inducible perfusion defects. No significant prognostic differences were found between I-LGE and NI-LGE. CONCLUSION NI-LGE can be detected in 11% of patients during stress-CMR providing a diagnosis of nonischemic cardiac disease. Patients with NI-LGE have worse prognosis than those with no-LGE.
Collapse
Affiliation(s)
- Chrysanthos Grigoratos
- Fondazione Gabriele Monasterio CNR/Regione Toscana.,Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy
| | | | - Christophe T Arendt
- Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Doris Leithner
- Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Cinzia Nugara
- Fondazione Gabriele Monasterio CNR/Regione Toscana.,Division of Cardiology and Cardiovascular Rehabilitation, Department of Internal Medicine and Cardiovascular Disease, University Hospital Paolo Giaccone, Palermo, Italy
| | | | | | - Valentina O Puntmann
- DZHK Centre for Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Giuseppina Novo
- Division of Cardiology and Cardiovascular Rehabilitation, Department of Internal Medicine and Cardiovascular Disease, University Hospital Paolo Giaccone, Palermo, Italy
| | - Alessia Pepe
- Fondazione Gabriele Monasterio CNR/Regione Toscana
| | - Michele Emdin
- Fondazione Gabriele Monasterio CNR/Regione Toscana.,Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy
| | - Eike Nagel
- DZHK Centre for Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | | |
Collapse
|
16
|
de Leuw P, Arendt CT, Haberl AE, Froadinadl D, Kann G, Wolf T, Stephan C, Schuettfort G, Vasquez M, Arcari L, Zhou H, Zainal H, Gawor M, Vidalakis E, Kolentinis M, Albrecht MH, Escher F, Vogl TJ, Zeiher AM, Nagel E, Puntmann VO. Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV. JACC Cardiovasc Imaging 2021; 14:1548-1557. [PMID: 33865770 DOI: 10.1016/j.jcmg.2021.01.042] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 12/30/2020] [Accepted: 01/28/2021] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The goal of this study was to examine prognostic relationships between cardiac imaging measures and cardiovascular outcome in people living with human immunodeficiency virus (HIV) (PLWH) on highly active antiretroviral therapy (HAART). BACKGROUND PLWH have a higher prevalence of cardiovascular disease and heart failure (HF) compared with the noninfected population. The pathophysiological drivers of myocardial dysfunction and worse cardiovascular outcome in HIV remain poorly understood. METHODS This prospective observational longitudinal study included consecutive PLWH on long-term HAART undergoing cardiac magnetic resonance (CMR) examination for assessment of myocardial volumes and function, T1 and T2 mapping, perfusion, and scar. Time-to-event analysis was performed from the index CMR examination to the first single event per patient. The primary endpoint was an adjudicated adverse cardiovascular event (cardiovascular mortality, nonfatal acute coronary syndrome, an appropriate device discharge, or a documented HF hospitalization). RESULTS A total of 156 participants (62% male; age [median, interquartile range]: 50 years [42 to 57 years]) were included. During a median follow-up of 13 months (9 to 19 months), 24 events were observed (4 HF deaths, 1 sudden cardiac death, 2 nonfatal acute myocardial infarction, 1 appropriate device discharge, and 16 HF hospitalizations). Patients with events had higher native T1 (median [interquartile range]: 1,149 ms [1,115 to 1,163 ms] vs. 1,110 ms [1,075 to 1,138 ms]); native T2 (40 ms [38 to 41 ms] vs. 37 ms [36 to 39 ms]); left ventricular (LV) mass index (65 g/m2 [49 to 77 g/m2] vs. 57 g/m2 [49 to 64 g/m2]), and N-terminal pro-B-type natriuretic peptide (109 pg/l [25 to 337 pg/l] vs. 48 pg/l [23 to 82 pg/l]) (all p < 0.05). In multivariable analyses, native T1 was independently predictive of adverse events (chi-square test, 15.9; p < 0.001; native T1 [10 ms] hazard ratio [95% confidence interval]: 1.20 [1.08 to 1.33]; p = 0.001), followed by a model that also included LV mass (chi-square test, 17.1; p < 0.001). Traditional cardiovascular risk scores were not predictive of the adverse events. CONCLUSIONS Our findings reveal important prognostic associations of diffuse myocardial fibrosis and LV remodeling in PLWH. These results may support development of personalized approaches to screening and early intervention to reduce the burden of HF in PLWH (International T1 Multicenter Outcome Study; NCT03749343).
Collapse
Affiliation(s)
- Philipp de Leuw
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany; Infektiologikum, Frankfurt am Main, Germany
| | - Christophe T Arendt
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Annette E Haberl
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Daniel Froadinadl
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Gerrit Kann
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Timo Wolf
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Christoph Stephan
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Gundolf Schuettfort
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Moises Vasquez
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Cardiology Department, Enrique Baltodano Briceño Hospital, Liberia, Costa Rica
| | - Luca Arcari
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
| | - Hui Zhou
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, XiangYa Hospital, Central South University, Changsha, Hunan, China
| | - Hafisyatul Zainal
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Universiti Teknologi MARA (UiTM), Sg. Buloh, Malaysia
| | - Monika Gawor
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital Warsaw, Warsaw, Poland
| | - Eleftherios Vidalakis
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Michael Kolentinis
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Moritz H Albrecht
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Thomas J Vogl
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Andreas M Zeiher
- Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital Warsaw, Warsaw, Poland.
| |
Collapse
|
17
|
Alabed S, Saunders L, Garg P, Shahin Y, Alandejani F, Rolf A, Puntmann VO, Nagel E, Wild JM, Kiely DG, Swift AJ. Myocardial T1-mapping and extracellular volume in pulmonary arterial hypertension: A systematic review and meta-analysis. Magn Reson Imaging 2021; 79:66-75. [PMID: 33745961 DOI: 10.1016/j.mri.2021.03.011] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 03/10/2021] [Accepted: 03/13/2021] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Elevated myocardial T1-mapping and extracellular volume (ECV) measured on cardiac MR (CMR) imaging is associated with myocardial abnormalities such as oedema or fibrosis. This meta-analysis aims to provide a summary of T1-mapping and ECV values in pulmonary arterial hypertension (PAH) and compare their values with controls. METHODS We searched CENTRAL, MEDLINE, Embase, and Web of Science in August 2020. We included CMR studies reporting T1-mapping or ECV values in adults with any type of PAH. We calculated the mean difference of T1-values and ECV between PAH and controls. RESULTS We included 12 studies with 674 participants. T1-values were significantly higher in PAH with the highest mean difference (MD) recorded at the RV insertion points (RVIP) (108 milliseconds (ms), 95% confidence intervals (CI) 89 to 128), followed by the RV free wall (MD 91 ms, 95% CI 56 to 126). The pooled mean T1-value in PAH at the RVIP was 1084, 95% CI (1071 to 1097) measured using 1.5 Tesla Siemens systems. ECV was also higher in PAH with an MD of 7.5%, 95% CI (5.9 to 9.1) at the RV free wall. CONCLUSION T1 mapping values in PAH patients are on average 9% higher than healthy controls when assessed under the same conditions including the same MRI system, magnetic field strength or sequence used for acquisition. The highest T1 and ECV values are at the RVIP. T1 mapping and ECV values in PH are higher than the values reported in cardiomyopathies and were associated with poor RV function and RV dilatation.
Collapse
Affiliation(s)
- Samer Alabed
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Clinical Radiology, Sheffield Teaching Hospitals, Sheffield, UK.
| | - Laura Saunders
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Pankaj Garg
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Yousef Shahin
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Clinical Radiology, Sheffield Teaching Hospitals, Sheffield, UK
| | - Faisal Alandejani
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Andreas Rolf
- Department of Cardiology, Kerckhoff-Heart Center, Bad Nauheim, Germany
| | - Valentina O Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Jim M Wild
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; INSIGNEO, Institute for in silico medicine, University of Sheffield, UK
| | - David G Kiely
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
| | - Andrew J Swift
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Clinical Radiology, Sheffield Teaching Hospitals, Sheffield, UK; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
| |
Collapse
|
18
|
Mia I, Le M, Arendt C, Brand D, Bremekamp S, D’Angelo T, Puntmann VO, Nagel E. Quantitative perfusion-CMR is significantly influenced by the placement of the arterial input function. Int J Cardiovasc Imaging 2021; 37:1023-1031. [PMID: 33047177 PMCID: PMC7969553 DOI: 10.1007/s10554-020-02049-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 09/26/2020] [Indexed: 11/29/2022]
Abstract
The aim of this study is to provide a systematic assessment of the influence of the position on the arterial input function (AIF) for perfusion quantification. In 39 patients with a wide range of left ventricular function the AIF was determined using a diluted contrast bolus of a cardiac magnetic resonance imaging in three left ventricular levels (basal, mid, apex) as well as aortic sinus (AoS). Time to peak signal intensities, baseline corrected peak signal intensity and upslopes were determined and compared to those obtained in the AoS. The error induced by sampling the AIF in a position different to the AoS was determined by Fermi deconvolution. The time to peak signal intensity was strongly correlated (r2 > 0.9) for all positions with a systematic earlier arrival in the basal (- 2153 ± 818 ms), the mid (- 1429 ± 928 ms) and the apical slice (- 450 ± 739 ms) relative to the AoS (all p < 0.001). Peak signal intensity as well as upslopes were strongly correlated (r2 > 0.9 for both) for all positions with a systematic overestimation in all positions relative to the AoS (all p < 0.001 and all p < 0.05). Differences between the positions were more pronounced for patients with reduced ejection fraction. The error of averaged MBF quantification was 8%, 13% and 27% for the base, mid and apex. The location of the AIF significantly influences core parameters for perfusion quantification with a systematic and ejection fraction dependent error. Full quantification should be based on obtaining the AIF as close as possible to the myocardium to minimize these errors.
Collapse
Affiliation(s)
- Ibnul Mia
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital, Goethe University, Frankfurt am Main, Germany
| | - Melanie Le
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Christophe Arendt
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Diana Brand
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Sina Bremekamp
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Tommaso D’Angelo
- Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Via Consolare Valeria 1, 98100 Messina, Italy
| | - Valentina O. Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital, Goethe University, Frankfurt am Main, Germany
| |
Collapse
|
19
|
Kolentinis M, Carerj LM, Vidalakis E, Gawor M, Vasquez M, D Angelo T, Arcari L, Zainal H, Zhou H, Abrecht M, Arendt C, Vogl TJ, Nagel E, Puntmann VO. Determination of scar area using native and post contrast T1 mapping: a validation study. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public Institution(s). Main funding source(s): Goethe University Hospital
Introduction
Late gadolinium enhancement (LGE) with Full Width Half Maximum (FWHM) is the standard imaging method for the measurement of the scar area in ischemic heart disease, a major determinant of adverse outcome. T1 mapping techniques have become increasingly applied in everyday clinical practice. Agreement in area quantification between T1 mapping and LGE for the scar extent has not been systematically assessed.
Purpose
This study aims to ascertain concordance between the area determined by native and post contrast T1 mapping against LGE to determine scar area in patients with a prior myocardial infarction. It also examines intra and inter-observer reproducibility for these two methods.
Methods
Subendocardial scar was evaluated in 132 patients with ischemic heart disease using LGE, native and post contrast T1 mapping in 3 short axis slices. Native and postcontrast T1 mapping was performed using GoetheCVI®MOLLI sequence (Gadovist® 0.1mmol/kg). FWHM method was applied for LGE and compared with the manually delineated area of scar in native and postcontrast T1 mapping acquisitions within the identical slices. The presence of the scar was defined as LGE >3% of the myocardial mass. Bland-Altman methods were employed to assess concordance between techniques and reproducibly between observers.
Results
In comparison to LGE, area measurements in native T1 acquisitions underestimated infarct size (9,1% vs 12,6%, p = 0.01), while postcontrast T1 overestimated it (19,4% vs 12,6%, p < 0.001). The disparity between the measurements was accentuated with larger scar areas (Figure 1). Intraobserver reproducibility (native T1: intra/inter MD ± SD, CoV, postcontrast T1: intra/inter) was similar with both methods, whereas interobserver variability for native T1 mapping acquisition was worse.
Conclusions
We demonstrate that measurements of the area of myocardial scar by T1 mapping acquisitions yield considerably different results in comparison to the standard LGE-based FWHM method. High observer agreement indicates that these differences are genuinely related to the type of the underlying acquisition and the differences in detected signal. The approaches are not interchangeable. However, the importance of these results for predicting patient outcome is yet to be elucidated. Nonetheless, these results were consistent in the inter and intraobserver analysis for post contrast T1 mapping, although native T1 mapping failed to show similar consistency.
Figure 1: Bland-Altmann plot of differences (mean ± upper and lower limit of agreement-LOA) in scar area extent (percentage) between LGE and native T1 mapping (A), LGE and post contrast T1 mapping (B). The difference increases linearly for larger scar areas when using post contrast mapping, which does not apply for native mapping.
Abstract Figure 1
Collapse
Affiliation(s)
- M Kolentinis
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - LM Carerj
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - E Vidalakis
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - M Gawor
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - M Vasquez
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - T D Angelo
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - L Arcari
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - H Zainal
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - H Zhou
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - M Abrecht
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - C Arendt
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - TJ Vogl
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - E Nagel
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| | - VO Puntmann
- Cardiology Frankfurt Sachsenhausen, Frankfurt, Germany
| |
Collapse
|
20
|
Pathan F, Zainal Abidin HA, Vo QH, Zhou H, D'Angelo T, Elen E, Negishi K, Puntmann VO, Marwick TH, Nagel E. Left atrial strain: a multi-modality, multi-vendor comparison study. Eur Heart J Cardiovasc Imaging 2021; 22:102-110. [PMID: 31848575 DOI: 10.1093/ehjci/jez303] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 09/08/2019] [Accepted: 11/17/2019] [Indexed: 01/14/2023] Open
Abstract
AIMS Left atrial (LA) strain is a prognostic biomarker with utility across a spectrum of acute and chronic cardiovascular pathologies. There are limited data on intervendor differences and no data on intermodality differences for LA strain. We sought to compare the intervendor and intermodality differences between transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) derived LA strain. We hypothesized that various components of atrial strain would show good intervendor and intermodality correlation but that there would be systematic differences between vendors and modalities. METHODS AND RESULTS We evaluated 54 subjects (43 patients with a clinical indication for CMR and 11 healthy volunteers) in a study comparing TTE- and CMR-derived LA reservoir strain (ƐR), conduit strain (ƐCD), and contractile strain (ƐCT). The LA strain components were evaluated using four dedicated types of post-processing software. We evaluated the correlation and systematic bias between modalities and within each modality. Intervendor and intermodality correlation was: ƐR [intraclass correlation coefficient (ICC 0.64-0.90)], ƐCD (ICC 0.62-0.89), and ƐCT (ICC 0.58-0.77). There was evidence of systematic bias between vendors and modalities with mean differences ranging from (3.1-12.2%) for ƐR, ƐCD (1.6-8.6%), and ƐCT (0.3-3.6%). Reproducibility analysis revealed intraobserver coefficient of variance (COV) of 6.5-14.6% and interobserver COV of 9.9-18.7%. CONCLUSION Vendor derived ƐR, ƐCD, and ƐCT demonstrates modest to excellent intervendor and intermodality correlation depending on strain component examined. There are systematic differences in measurements depending on modality and vendor. These differences may be addressed by future studies, which, examine calibration of LA geometry/higher frame rate imaging, semi-quantitative approaches, and improvements in reproducibility.
Collapse
Affiliation(s)
- Faraz Pathan
- Department of Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Cardiovascular Imaging, Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, Australia.,Department of Cardiovascular Imaging, University of Sydney, Nepean Clinical School, Sydney, Australia
| | - Hafisyatul Aiza Zainal Abidin
- Department of Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Cardiology, Faculty of Medicine, Universiti Teknologi MARA, Kuala Lampur, Malaysia
| | - Quang Ha Vo
- Department of Cardiovascular Imaging, Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, Australia
| | - Hui Zhou
- Department of Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Radiology, XiangYa Hospital, Central South University, Hunan, China
| | - Tommaso D'Angelo
- Department of Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital, Messina, Italy
| | - Elen Elen
- Department of Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Cardiology, National Cardiovascular Center Harapan Kita, Universitas, Jakarta, Indonesia
| | - Kazuaki Negishi
- Department of Cardiovascular Imaging, Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, Australia.,Department of Cardiovascular Imaging, University of Sydney, Nepean Clinical School, Sydney, Australia
| | - Valentina O Puntmann
- Department of Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Thomas H Marwick
- Department of Cardiovascular Imaging, Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, Australia.,Department of Cardiovascular Imaging, Baker Heart and Diabetes Institute, Melbourne, Australia
| | - Eike Nagel
- Department of Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
21
|
Abstract
Introduction: COVID-19 is causing considerable morbidity and mortality worldwide. Serious respiratory complications aside, the heart is also frequently involved. The mechanisms and the extent of the myocardial injury, along with the short and long-term cardiovascular (CV) outcomes in COVID-19 survivors remain unclear. Areas covered: myocardial injury has been found in a considerable proportion of hospitalized COVID-19 patients and is associated with a worse prognosis. The late onset of CV complications with myocarditis-like changes revealed by CMR has been reported in COVID-19 survivors. Previous observational studies on viral myocarditis provide evidence of a significant incomplete recovery with residual dysfunction and remodeling of left ventricle. Incomplete recovery is thought to be the result of persistent myocardial inflammation due to a post-viral autoimmune response. Considering the significant inflammatory nature of COVID-19, COVID-19 survivors may be at risk of developing persistent residual myocardial injury, the sequelae of which are unclear. Expert commentary: COVID-19 is an emerging threat for the heart. The extent of CV injury, along with the short and long-term sequelae, requires further investigation. The early detection of residual myocardial changes in COVID-19 survivors is of utmost importance in order to identify those patients at risk of CV complication development.
Collapse
Affiliation(s)
- Anastasia Shchendrygina
- Department of Hospital Therapy №1, I.M. Sechenov First Moscow State Medical University (Sechenov University) , Moscow, Russian Federation
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt , Frankfurt, Germany
| | - Valentina O Puntmann
- Department of Cardiology, Division of Internal Medicine III, Goethe University Hospital Frankfurt , Frankfurt, Germany
| | | |
Collapse
|
22
|
Nagel E, Puntmann VO. Errors in Statistical Numbers and Data in Study of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From COVID-19. JAMA Cardiol 2020; 5:1307-1308. [PMID: 32840561 DOI: 10.1001/jamacardio.2020.4661] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
23
|
Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5:1265-1273. [PMID: 32730619 PMCID: PMC7385689 DOI: 10.1001/jamacardio.2020.3557] [Citation(s) in RCA: 1346] [Impact Index Per Article: 336.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
IMPORTANCE Coronavirus disease 2019 (COVID-19) continues to cause considerable morbidity and mortality worldwide. Case reports of hospitalized patients suggest that COVID-19 prominently affects the cardiovascular system, but the overall impact remains unknown. OBJECTIVE To evaluate the presence of myocardial injury in unselected patients recently recovered from COVID-19 illness. DESIGN, SETTING, AND PARTICIPANTS In this prospective observational cohort study, 100 patients recently recovered from COVID-19 illness were identified from the University Hospital Frankfurt COVID-19 Registry between April and June 2020. EXPOSURE Recent recovery from severe acute respiratory syndrome coronavirus 2 infection, as determined by reverse transcription-polymerase chain reaction on swab test of the upper respiratory tract. MAIN OUTCOMES AND MEASURES Demographic characteristics, cardiac blood markers, and cardiovascular magnetic resonance (CMR) imaging were obtained. Comparisons were made with age-matched and sex-matched control groups of healthy volunteers (n = 50) and risk factor-matched patients (n = 57). RESULTS Of the 100 included patients, 53 (53%) were male, and the mean (SD) age was 49 (14) years. The median (IQR) time interval between COVID-19 diagnosis and CMR was 71 (64-92) days. Of the 100 patients recently recovered from COVID-19, 67 (67%) recovered at home, while 33 (33%) required hospitalization. At the time of CMR, high-sensitivity troponin T (hsTnT) was detectable (greater than 3 pg/mL) in 71 patients recently recovered from COVID-19 (71%) and significantly elevated (greater than 13.9 pg/mL) in 5 patients (5%). Compared with healthy controls and risk factor-matched controls, patients recently recovered from COVID-19 had lower left ventricular ejection fraction, higher left ventricle volumes, and raised native T1 and T2. A total of 78 patients recently recovered from COVID-19 (78%) had abnormal CMR findings, including raised myocardial native T1 (n = 73), raised myocardial native T2 (n = 60), myocardial late gadolinium enhancement (n = 32), or pericardial enhancement (n = 22). There was a small but significant difference between patients who recovered at home vs in the hospital for native T1 mapping (median [IQR], 1119 [1092-1150] ms vs 1141 [1121-1175] ms; P = .008) and hsTnT (4.2 [3.0-5.9] pg/dL vs 6.3 [3.4-7.9] pg/dL; P = .002) but not for native T2 mapping. None of these measures were correlated with time from COVID-19 diagnosis (native T1: r = 0.07; P = .47; native T2: r = 0.14; P = .15; hsTnT: r = -0.07; P = .50). High-sensitivity troponin T was significantly correlated with native T1 mapping (r = 0.33; P < .001) and native T2 mapping (r = 0.18; P = .01). Endomyocardial biopsy in patients with severe findings revealed active lymphocytic inflammation. Native T1 and T2 were the measures with the best discriminatory ability to detect COVID-19-related myocardial pathology. CONCLUSIONS AND RELEVANCE In this study of a cohort of German patients recently recovered from COVID-19 infection, CMR revealed cardiac involvement in 78 patients (78%) and ongoing myocardial inflammation in 60 patients (60%), independent of preexisting conditions, severity and overall course of the acute illness, and time from the original diagnosis. These findings indicate the need for ongoing investigation of the long-term cardiovascular consequences of COVID-19.
Collapse
Affiliation(s)
- Valentina O. Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - M. Ludovica Carerj
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany,Department of Biomedical Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy
| | - Imke Wieters
- Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Masia Fahim
- Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Christophe Arendt
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany,Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Jedrzej Hoffmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany,Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Anastasia Shchendrygina
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany,Department of Hospital Therapy No. 1, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | | | - Mariuca Vasa-Nicotera
- Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Andreas M. Zeiher
- Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Maria Vehreschild
- Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
24
|
Hoffmann J, Puntmann VO, Fišer K, Rasper T, Berkowitsch A, Carerj ML, Nagel E, Dimmeler S, Zeiher AM. Circulating Th17 and Th22 Cells Are Associated With CMR Imaging Biosignatures of Diffuse Myocardial Interstitial Remodeling in Chronic Coronary Artery Disease. Circ Res 2020; 127:699-701. [PMID: 32576092 PMCID: PMC7418928 DOI: 10.1161/circresaha.120.316619] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Jedrzej Hoffmann
- From the Departments of Medicine and Cardiology (J.H., V.O.P., A.B., E.N., A.M.Z.), Goethe University, Frankfurt, Germany
- Institute for Experimental and Translational Cardiovascular Imaging (J.H., V.O.P., M.L.C., E.N., S.D.), Goethe University, Frankfurt, Germany
- German Center for Cardiovascular Research DZHK, Berlin, Germany, partner site Rhine-Main (J.H., V.O.P., E.N., S.D., A.M.Z.)
| | - Valentina O. Puntmann
- From the Departments of Medicine and Cardiology (J.H., V.O.P., A.B., E.N., A.M.Z.), Goethe University, Frankfurt, Germany
- Institute for Experimental and Translational Cardiovascular Imaging (J.H., V.O.P., M.L.C., E.N., S.D.), Goethe University, Frankfurt, Germany
- German Center for Cardiovascular Research DZHK, Berlin, Germany, partner site Rhine-Main (J.H., V.O.P., E.N., S.D., A.M.Z.)
| | - Karel Fišer
- Department of Pediatric Haematology and Oncology, CLIP—Childhood Leukemia Investigation Prague, Charles University, Czech Republic (K.F.)
| | - Tina Rasper
- Institute of Cardiovascular Regeneration, Center of Molecular Medicine (T.R., S.D.), Goethe University, Frankfurt, Germany
| | - Alexander Berkowitsch
- From the Departments of Medicine and Cardiology (J.H., V.O.P., A.B., E.N., A.M.Z.), Goethe University, Frankfurt, Germany
| | - Maria Ludovica Carerj
- Institute for Experimental and Translational Cardiovascular Imaging (J.H., V.O.P., M.L.C., E.N., S.D.), Goethe University, Frankfurt, Germany
| | - Eike Nagel
- From the Departments of Medicine and Cardiology (J.H., V.O.P., A.B., E.N., A.M.Z.), Goethe University, Frankfurt, Germany
- Institute for Experimental and Translational Cardiovascular Imaging (J.H., V.O.P., M.L.C., E.N., S.D.), Goethe University, Frankfurt, Germany
- German Center for Cardiovascular Research DZHK, Berlin, Germany, partner site Rhine-Main (J.H., V.O.P., E.N., S.D., A.M.Z.)
| | - Stefanie Dimmeler
- Institute for Experimental and Translational Cardiovascular Imaging (J.H., V.O.P., M.L.C., E.N., S.D.), Goethe University, Frankfurt, Germany
- Institute of Cardiovascular Regeneration, Center of Molecular Medicine (T.R., S.D.), Goethe University, Frankfurt, Germany
- German Center for Cardiovascular Research DZHK, Berlin, Germany, partner site Rhine-Main (J.H., V.O.P., E.N., S.D., A.M.Z.)
| | - Andreas M. Zeiher
- From the Departments of Medicine and Cardiology (J.H., V.O.P., A.B., E.N., A.M.Z.), Goethe University, Frankfurt, Germany
- German Center for Cardiovascular Research DZHK, Berlin, Germany, partner site Rhine-Main (J.H., V.O.P., E.N., S.D., A.M.Z.)
| |
Collapse
|
25
|
Nagel E, Carerj ML, Arendt CT, Puntmann VO. Erratum to: After ISCHEMIA: Is cardiac MRI a reliable gatekeeper for invasive angiography and myocardial revascularization? Herz 2020; 45:505. [PMID: 32613316 DOI: 10.1007/s00059-020-04963-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In the above mentioned article, the family name of the second author was not given correctly: it is Carerj instead of Careri.The authors apologize for this mistake.The original article has been ….
Collapse
Affiliation(s)
- E Nagel
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
| | - M L Carerj
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- Section of Radiological Sciences, Department of Biomedical Sciences and Morphological and Functional; Imaging, Policlinico G. Martino, University Hospital Messina, Messina, Italy
| | - C T Arendt
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - V O Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| |
Collapse
|
26
|
Abstract
Chronic coronary artery disease remains an unconquered clinical problem, affecting an increasing number of people worldwide. Despite the improved understanding of the disease development, the implementation of the many advances in diagnosis and therapy is lacking. Many clinicians continue to rely on patient’s symptoms and diagnostic methods, which do not enable optimal clinical decisions. For example, echocardiography and invasive coronary catheterisation remain the mainstay investigations for stable angina patients in many places, despite the evidence on their limitations and availability of better diagnostic options. Cardiac MRI is a powerful diagnostic method, supporting robust measurements of crucial markers of cardiac structure and function, myocardial perfusion and scar, as well as providing detailed insight into myocardial tissue. Accurate and informative diagnostic readouts can help with guiding therapy, monitoring disease progress and tailoring the response to treatment. In this article, the authors outline the evidence supporting the state-of-art applications based on cardiovascular magnetic resonance, allowing the clinician optimal use of this insightful diagnostic method in everyday clinical practice.
Collapse
Affiliation(s)
- Michalis Kolentinis
- Institute of Experimental and Translational Cardiovascular Imaging, German Centre for Cardiovascular Research (DZHK) Centre for Cardiovascular Imaging, Partner Site Rhein-Main, University Hospital Frankfurt Frankfurt, Germany
| | - Melanie Le
- Institute of Experimental and Translational Cardiovascular Imaging, German Centre for Cardiovascular Research (DZHK) Centre for Cardiovascular Imaging, Partner Site Rhein-Main, University Hospital Frankfurt Frankfurt, Germany
| | - Eike Nagel
- Institute of Experimental and Translational Cardiovascular Imaging, German Centre for Cardiovascular Research (DZHK) Centre for Cardiovascular Imaging, Partner Site Rhein-Main, University Hospital Frankfurt Frankfurt, Germany
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiovascular Imaging, German Centre for Cardiovascular Research (DZHK) Centre for Cardiovascular Imaging, Partner Site Rhein-Main, University Hospital Frankfurt Frankfurt, Germany
| |
Collapse
|
27
|
Arcari L, Hinojar R, Engel J, Freiwald T, Platschek S, Zainal H, Zhou H, Vasquez M, Keller T, Rolf A, Geiger H, Hauser I, Vogl TJ, Zeiher AM, Volpe M, Nagel E, Puntmann VO. Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions - Comparison of uremic, hypertensive and hypertrophic cardiomyopathy. Int J Cardiol 2020; 306:102-108. [PMID: 32169347 DOI: 10.1016/j.ijcard.2020.03.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Revised: 02/26/2020] [Accepted: 03/02/2020] [Indexed: 02/06/2023]
Abstract
AIMS Profound left ventricular (LV) hypertrophy with diastolic dysfunction and heart failure is the cardinal manifestation of heart remodelling in chronic kidney disease (CKD). Previous studies related increased T1 mapping values in CKD with diffuse fibrosis. Native T1 is a non-specific readout that may also relate to increased intramyocardial fluid. We examined concomitant T1 and T2 mapping signatures and undertook comparisons with other hypertrophic conditions. METHODS In this prospective multicentre study, consecutive CKD patients (n = 154) undergoing routine clinical cardiac magnetic resonance (CMR) imaging were compared with patients with hypertensive (HTN, n = 163) and hypertrophic cardiomyopathy (HCM, n = 158), and normotensive controls (n = 133). RESULTS Native T1 was significantly higher in all patient groups, whereas native T2 in CKD only (p < 0.001 vs. all groups). Native T1 and T2 were interrelated in patient groups and the strength of association was condition-specific (CKD r = 0.558, HTN r = 0.324, both p < 0.001; HCM r = 0.157, p = 0.05). Native T1 and T2 were similarly correlated in all CKD stages (S3 r = 0.501, S4 0.586, S5 r = 0.424, p < 0.001 for all). Native T1 was the strongest myocardial discriminator between patients and controls (area under the curve, AUC HCM: 0.97; CKD: 0.97, HTN 0.98), native T2 between CKD vs HCM (AUC 0.90) and native T1 and T2 between CKD vs HTN (AUC: 0.83 and 0.80 respectively), p < 0.001 for all. CONCLUSIONS Our findings reveal different CMR signatures of common hypertrophic cardiac phenotypes. Native T1 was raised in all conditions, indicating the presence of pathologic hypertrophic remodelling. Markedly raised native T2 was CKD-specific, suggesting a prominent role of intramyocardial fluid.
Collapse
Affiliation(s)
- Luca Arcari
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Cardiology Unit, Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy
| | - Rocio Hinojar
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain
| | - Juergen Engel
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfuret-am Main, Germany
| | - Tilo Freiwald
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfuret-am Main, Germany
| | - Steffen Platschek
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfuret-am Main, Germany
| | - Hafisyatul Zainal
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Universiti Teknologi MARA (UiTM), Sg. Buloh, Malaysia
| | - Hui Zhou
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, XiangYa Hospital, Central South University, Changsha, Hunan, China
| | - Moises Vasquez
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Enrique Baltodano Briceño Hospital, Liberia, Costa Rica
| | - Till Keller
- Department of Cardiology, Kerckhoff Hospital, University Giessen, Bad Nauheim, Germany
| | - Andreas Rolf
- Department of Cardiology, Kerckhoff Hospital, University Giessen, Bad Nauheim, Germany
| | - Helmut Geiger
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfuret-am Main, Germany
| | - Ingeborg Hauser
- Department of Nephrology, Goethe University Hospital Frankfurt, Frankfuret-am Main, Germany
| | - Thomas J Vogl
- Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Andreas M Zeiher
- Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Massimo Volpe
- Cardiology Unit, Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy
| | - Eike Nagel
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt-am Main, Germany.
| |
Collapse
|
28
|
Le MTP, Zarinabad N, D’Angelo T, Mia I, Heinke R, Vogl TJ, Zeiher A, Nagel E, Puntmann VO. Sub-segmental quantification of single (stress)-pass perfusion CMR improves the diagnostic accuracy for detection of obstructive coronary artery disease. J Cardiovasc Magn Reson 2020; 22:14. [PMID: 32028980 PMCID: PMC7006214 DOI: 10.1186/s12968-020-0600-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 01/07/2020] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Myocardial perfusion with cardiovascular magnetic resonance (CMR) imaging is an established diagnostic test for evaluation of myocardial ischaemia. For quantification purposes, the 16 segment American Heart Association (AHA) model poses limitations in terms of extracting relevant information on the extent/severity of ischaemia as perfusion deficits will not always fall within an individual segment, which reduces its diagnostic value, and makes an accurate assessment of outcome data or a result comparison across various studies difficult. We hypothesised that division of the myocardial segments into epi- and endocardial layers and a further circumferential subdivision, resulting in a total of 96 segments, would improve the accuracy of detecting myocardial hypoperfusion. Higher (sub-)subsegmental recording of perfusion abnormalities, which are defined relatively to the normal reference using the subsegment with the highest value, may improve the spatial encoding of myocardial blood flow, based on a single stress perfusion acquisition. OBJECTIVE A proof of concept comparison study of subsegmentation approaches based on transmural segments (16 AHA and 48 segments) vs. subdivision into epi- and endocardial (32) subsegments vs. further circumferential subdivision into 96 (sub-)subsegments for diagnostic accuracy against invasively defined obstructive coronary artery disease (CAD). METHODS Thirty patients with obstructive CAD and 20 healthy controls underwent perfusion stress CMR imaging at 3 T during maximal adenosine vasodilation and a dual bolus injection of 0.1 mmol/kg gadobutrol. Using Fermi deconvolution for blood flow estimation, (sub-)subsegmental values were expressed relative to the (sub-)subsegment with the highest flow. In addition, endo-/epicardial flow ratios were calculated based on 32 and 96 (sub-)subsegments. A receiver operating characteristics (ROC) curve analysis was performed to compare the diagnostic performance of discrimination between patients with CAD and healthy controls. Observer reproducibility was assessed using Bland-Altman approaches. RESULTS Subdivision into more and smaller segments revealed greater accuracy for #32, #48 and # 96 compared to the standard #16 approach (area under the curve (AUC): 0.937, 0.973 and 0.993 vs 0.820, p < 0.05). The #96-based endo-/epicardial ratio was superior to the #32 endo-/epicardial ratio (AUC 0.979, vs. 0.932, p < 0.05). Measurements for the #16 model showed marginally better reproducibility compared to #32, #48 and #96 (mean difference ± standard deviation: 2.0 ± 3.6 vs. 2.3 ± 4.0 vs 2.5 ± 4.4 vs. 4.1 ± 5.6). CONCLUSIONS Subsegmentation of the myocardium improves diagnostic accuracy and facilitates an objective cut-off-based description of hypoperfusion, and facilitates an objective description of hypoperfusion, including the extent and severity of myocardial ischaemia. Quantification based on a single (stress-only) pass reduces the overall amount of gadolinium contrast agent required and the length of the overall diagnostic study.
Collapse
Affiliation(s)
- Melanie T. P. Le
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Niloufar Zarinabad
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Tommaso D’Angelo
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
- Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Via Consolare Valeria 1, Messina, 98100 Italy
| | - Ibnul Mia
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Robert Heinke
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Thomas J. Vogl
- Department of Radiology, University Hospital Frankfurt, Theodor-Stern Kai 7, Frankfurt am Main, Germany
| | - Andreas Zeiher
- Department of Cardiology, University Hospital Frankfurt, Theodor-Stern Kai 7, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
| | - Valentina O. Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt am Main, Germany
- Department of Cardiology, University Hospital Frankfurt, Theodor-Stern Kai 7, Frankfurt am Main, Germany
| |
Collapse
|
29
|
Heinke R, Pathan F, Le M, D'Angelo T, Winau L, Arendt C, Vogl TJ, Zeiher A, Nagel E, Puntmann VO. Towards standardized postprocessing of global longitudinal strain by feature tracking - OptiStrain CMR-FT study. BMC Cardiovasc Disord 2019; 19:267. [PMID: 31775656 PMCID: PMC6882184 DOI: 10.1186/s12872-019-1255-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 11/12/2019] [Indexed: 02/05/2023] Open
Abstract
Background Left ventricular global longitudinal strain (GLS) with cardiovascular magnetic resonance (CMR) is an important prognostic biomarker. Its everyday clinical use is limited due to methodological and postprocessing diversity among the users and vendors. Standardization of postprocessing approaches may reduce the random operator-dependent variability, allowing for comparability of measurements despite the systematic vendor-related differences. Methods We investigated the random component of variability in GLS measurements by optimization steps which incrementally improved observer reproducibility and agreement. Cine images in two-, three- and four-chamber-views were serially analysed by two independent observers using two different CMR-FT softwares. The disparity of outcomes after each series was systematically assessed after a number of stepwise adjustments which were shown to significantly reduce the inter-observer and intervendor bias, resulting standardized postprocessing approach. The final analysis was performed in 44 subjects (ischaemic heart disease n = 15, non-ischaemic dilated cardiomyopathy, n = 19, healthy controls, n = 10). All measurements were performed blind to the underlying group allocation and previous measurements. Inter- and intra-observer variability were tested using Bland-Altman analyses, intra-class correlation coefficients (ICCs) and coefficients of variation (CVs). Results Compared to controls, mean GLS was significantly lower in patients, as well as between the two subgroups (p < 0.01). These differences were accentuated by standardization procedures, with significant increase in Cohen’s D and AUCs. The benefit of standardization was also evident through improved CV and ICC agreements between observers and the two vendors. Initial intra-observer variability CVs for GLS parameters were 7.6 and 4.6%, inter-observer variability CVs were 11 and 4.7%, for the two vendors, respectively. After standardization, intra- and interobserver variability CVs were 3.1 and 4.3%, and 5.2 and 4.4%, respectively. Conclusion Standardization of GLS postprocessing helps to reduce the random component of variability, introduced by inconsistencies of and between observers, and also intervendor variability, but not the systematic inter-vendor bias due to differences in image processing algorithms. Standardization of GLS measurements is an essential step in ensuring the reliable quantification of myocardial deformation, and implementation of CMR-FT in clinical routine.
Collapse
Affiliation(s)
- Robert Heinke
- Institute of Experimental and Translational Cardiac Imaging DZHK Centre for Cardiovascular Imaging Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt am Main, Germany
| | - Faraz Pathan
- Institute of Experimental and Translational Cardiac Imaging DZHK Centre for Cardiovascular Imaging Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt am Main, Germany.,Department of Cardiovascular Imaging, Menzies Institute for Medical Research, Hobart, Tasmania, Australia
| | - Melanie Le
- Institute of Experimental and Translational Cardiac Imaging DZHK Centre for Cardiovascular Imaging Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt am Main, Germany
| | - Tommaso D'Angelo
- Institute of Experimental and Translational Cardiac Imaging DZHK Centre for Cardiovascular Imaging Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt am Main, Germany.,Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Messina, Italy
| | - Lea Winau
- Institute of Experimental and Translational Cardiac Imaging DZHK Centre for Cardiovascular Imaging Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt am Main, Germany
| | - Christophe Arendt
- Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Thomas J Vogl
- Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Andreas Zeiher
- Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Eike Nagel
- Institute of Experimental and Translational Cardiac Imaging DZHK Centre for Cardiovascular Imaging Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiac Imaging DZHK Centre for Cardiovascular Imaging Goethe University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt am Main, Germany. .,Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt-am Main, Germany.
| |
Collapse
|
30
|
Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S, Rolf A, Zitzmann S, Peker E, D'Angelo T, Pathan F, Elen, Valbuena S, Hinojar R, Arendt C, Narula J, Herrmann E, Zeiher AM, Nagel E. Native T1 and ECV of Noninfarcted Myocardium and Outcome in Patients With Coronary Artery Disease. J Am Coll Cardiol 2019; 71:766-778. [PMID: 29447739 DOI: 10.1016/j.jacc.2017.12.020] [Citation(s) in RCA: 68] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 12/07/2017] [Accepted: 12/07/2017] [Indexed: 02/06/2023]
Abstract
BACKGROUND Coronary artery disease (CAD) remains the major cause of cardiac morbidity and mortality worldwide, despite the advances in treatment with coronary revascularization and modern antiremodeling therapy. Risk stratification in CAD patients is primarily based on left ventricular volumes, ejection fraction (LVEF), risk scores, and the presence and extent of late gadolinium enhancement (LGE). The prognostic role of T1 mapping in noninfarcted myocardium in CAD patients has not yet been determined. OBJECTIVES This study sought to examine prognostic significance of native T1 mapping of noninfarcted myocardium in patients with CAD. METHODS A prospective, observational, multicenter longitudinal study of consecutive patients undergoing routine cardiac magnetic resonance imaging with T1 mapping and LGE. The primary endpoint was all-cause mortality. Major adverse cardiocerebrovascular events (MACCE) (cardiac mortality, nonfatal acute coronary syndrome, stroke, and appropriate device discharge) are also reported. RESULTS A total of 34 deaths and 71 MACCE (n = 665, males n = 424, median age [interquartile range] 57 [22] years; 64%; median follow-up period of 17 [11] months) were observed. Native T1 and extracellular volume were univariate predictors of outcome. Native T1 and LGE were stronger predictors of survival and MACCE compared with extracellular volume, LVEF, cardiac volumes, and clinical scores (p < 0.001). Native T1 of noninfarcted myocardium was the sole independent predictor of all-cause mortality (chi-square = 21.7; p < 0.001), which was accentuated in the absence of LGE or LVEF ≤35%. For MACCE, native T1 and LGE extent were joint independent predictors (chi-square = 25.6; p < 0.001). CONCLUSIONS Characterization of noninfarcted myocardium by native T1 is an important predictor of outcome in CAD patients, over and above the traditional risk stratifiers. The current study's results provide a basis for a novel risk stratification model in CAD based on a complementary assessment of noninfarcted myocardium and post-infarction scar, by native T1 mapping and LGE, respectively.
Collapse
Affiliation(s)
- Valentina O Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Cardiovascular Services, Guy's and St. Thomas' NHS Trust, London, United Kingdom; Department of Cardiology, University Hospital Frankfurt, Frankfurt-am Main, Germany.
| | - Gerry Carr-White
- Department of Cardiovascular Services, Guy's and St. Thomas' NHS Trust, London, United Kingdom; King's College Hospital NHS Trust, Denmark Hill, London, United Kingdom
| | - Andrew Jabbour
- Department of Cardiology, St. Vincent's University, Sydney, New South Wales, Australia
| | - Chung-Yao Yu
- Department of Cardiology, St. Vincent's University, Sydney, New South Wales, Australia
| | - Rolf Gebker
- Department of Cardiology, German Heart Institute Berlin, Berlin, Germany
| | - Sebastian Kelle
- Department of Cardiology, German Heart Institute Berlin, Berlin, Germany
| | - Andreas Rolf
- Department of Cardiology, Kerckhoff Hospital, University Giessen, Bad Nauheim, Germany
| | - Sabine Zitzmann
- Department of Cardiology, Kerckhoff Hospital, University Giessen, Bad Nauheim, Germany
| | - Elif Peker
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Radiology, Ankara University Hospital, Ankara, Turkey
| | - Tommaso D'Angelo
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Messina, Italy
| | - Faraz Pathan
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Cardiovascular Imaging, Menzies Institute for Medical Research, Hobart Tasmania, Australia
| | - Elen
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital Jakarta, Jakarta, Indonesia
| | - Silvia Valbuena
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital La Paz, Madrid, Spain
| | - Rocio Hinojar
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain
| | - Christophe Arendt
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Radiology, University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Jagat Narula
- Department of Cardiology, Mount Sinai School of Medicine, New York, New York
| | - Eva Herrmann
- DZHK Institute of Biostatistics and Mathematical Modelling at Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Andreas M Zeiher
- Department of Cardiology, University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Eike Nagel
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Cardiovascular Services, Guy's and St. Thomas' NHS Trust, London, United Kingdom; Department of Cardiology, University Hospital Frankfurt, Frankfurt-am Main, Germany; Department of Radiology, University Hospital Frankfurt, Frankfurt-am Main, Germany
| | | |
Collapse
|
31
|
Nagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST, Perera D, Plein S, Bucciarelli-Ducci C, Paul M, Westwood MA, Marber M, Richter WS, Puntmann VO, Schwenke C, Schulz-Menger J, Das R, Wong J, Hausenloy DJ, Steen H, Berry C. Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. N Engl J Med 2019; 380:2418-2428. [PMID: 31216398 DOI: 10.1056/nejmoa1716734] [Citation(s) in RCA: 287] [Impact Index Per Article: 57.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
BACKGROUND In patients with stable angina, two strategies are often used to guide revascularization: one involves myocardial-perfusion cardiovascular magnetic resonance imaging (MRI), and the other involves invasive angiography and measurement of fractional flow reserve (FFR). Whether a cardiovascular MRI-based strategy is noninferior to an FFR-based strategy with respect to major adverse cardiac events has not been established. METHODS We performed an unblinded, multicenter, clinical-effectiveness trial by randomly assigning 918 patients with typical angina and either two or more cardiovascular risk factors or a positive exercise treadmill test to a cardiovascular MRI-based strategy or an FFR-based strategy. Revascularization was recommended for patients in the cardiovascular-MRI group with ischemia in at least 6% of the myocardium or in the FFR group with an FFR of 0.8 or less. The composite primary outcome was death, nonfatal myocardial infarction, or target-vessel revascularization within 1 year. The noninferiority margin was a risk difference of 6 percentage points. RESULTS A total of 184 of 454 patients (40.5%) in the cardiovascular-MRI group and 213 of 464 patients (45.9%) in the FFR group met criteria to recommend revascularization (P = 0.11). Fewer patients in the cardiovascular-MRI group than in the FFR group underwent index revascularization (162 [35.7%] vs. 209 [45.0%], P = 0.005). The primary outcome occurred in 15 of 421 patients (3.6%) in the cardiovascular-MRI group and 16 of 430 patients (3.7%) in the FFR group (risk difference, -0.2 percentage points; 95% confidence interval, -2.7 to 2.4), findings that met the noninferiority threshold. The percentage of patients free from angina at 12 months did not differ significantly between the two groups (49.2% in the cardiovascular-MRI group and 43.8% in the FFR group, P = 0.21). CONCLUSIONS Among patients with stable angina and risk factors for coronary artery disease, myocardial-perfusion cardiovascular MRI was associated with a lower incidence of coronary revascularization than FFR and was noninferior to FFR with respect to major adverse cardiac events. (Funded by the Guy's and St. Thomas' Biomedical Research Centre of the National Institute for Health Research and others; MR-INFORM ClinicalTrials.gov number, NCT01236807.).
Collapse
Affiliation(s)
- Eike Nagel
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - John P Greenwood
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Gerry P McCann
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Nuno Bettencourt
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Ajay M Shah
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Shazia T Hussain
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Divaka Perera
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Sven Plein
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Chiara Bucciarelli-Ducci
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Matthias Paul
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Mark A Westwood
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Michael Marber
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Wolf-Stefan Richter
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Valentina O Puntmann
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Carsten Schwenke
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Jeanette Schulz-Menger
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Rajiv Das
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Joyce Wong
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Derek J Hausenloy
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Henning Steen
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| | - Colin Berry
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK (German Center for Cardiovascular Research) Center for Cardiovascular Imaging, Goethe University, and the Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main (E.N., V.O.P.), Pharmtrace (W.-S.R.), Schwenke Consulting (C.S.), and Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, DZHK, and Helios Kliniken Berlin-Buch (J.S.-M.), Berlin, and the Clinic for Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Heidelberg (H.S.) - all in Germany; the Division of Biomedical Engineering and Imaging Sciences (E.N., S.T.H., S.P., M.P.) and British Heart Foundation Centre (A.M.S., D.P., M.M.), King's College London, Barts Heart Centre, St. Bartholomew's Hospital (M.A.W.), the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London (D.J.H.), and the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (D.J.H.), London, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds (J.P.G., S.P.), the Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital (G.P.M.), and the Department of Cardiology, Glenfield Hospital (S.T.H.), Leicester, Bristol Heart Institute, University of Bristol and Bristol NIHR Biomedical Research Centre, Bristol (C.B.-D.), the Faculty of Health and Life Sciences, Northumbria University, and Freeman Hospital, Newcastle-upon-Tyne (R.D.), the Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Uxbridge (J.W.), and the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (C.B.) - all in the United Kingdom; Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal (N.B.); Kardiologie, Herzzentrum Luzern, Luzerner Kantonsspital, Lucerne, Switzerland (M.P.); and the Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, and the National Heart Research Institute Singapore, National Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (D.J.H.)
| |
Collapse
|
32
|
Zhou H, Zainal H, Puntmann VO. Non-infarcted myocardium bears the weight in CVD. Aging (Albany NY) 2019; 11:1609-1610. [PMID: 30908271 PMCID: PMC6461182 DOI: 10.18632/aging.101890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Accepted: 03/21/2019] [Indexed: 11/25/2022]
Affiliation(s)
- Hui Zhou
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Frankfurt, Germany.,Department of Radiology, XiangYa Hospital, Central South University, Changsha, Hunan, China
| | - Hafisyatul Zainal
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Frankfurt, Germany.,Department of Cardiology, Universiti Teknologi MARA (UiTM), Sg. Buloh, Malaysia
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Frankfurt, Germany
| |
Collapse
|
33
|
Saunders LC, Johns CS, Stewart NJ, Oram CJE, Capener DA, Puntmann VO, Elliot CA, Condliffe RC, Kiely DG, Graves MJ, Wild JM, Swift AJ. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson 2018; 20:78. [PMID: 30501639 PMCID: PMC6276188 DOI: 10.1186/s12968-018-0501-8] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 10/24/2018] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Native T1 may be a sensitive, contrast-free, non-invasive cardiovascular magnetic resonance (CMR) marker of myocardial tissue changes in patients with pulmonary artery hypertension. However, the diagnostic and prognostic value of native T1 mapping in this patient group has not been fully explored. The aim of this work was to determine whether elevation of native T1 in myocardial tissue in pulmonary hypertension: (a) varies according to pulmonary hypertension subtype; (b) has prognostic value and (c) is associated with ventricular function and interaction. METHODS Data were retrospectively collected from a total of 490 consecutive patients during their clinical 1.5 T CMR assessment at a pulmonary hypertension referral centre in 2015. Three hundred sixty-nine patients had pulmonary hypertension [58 ± 15 years; 66% female], an additional 39 had pulmonary hypertension due to left heart disease [68 ± 13 years; 60% female], 82 patients did not have pulmonary hypertension [55 ± 18; 68% female]. Twenty five healthy subjects were also recruited [58 ±4 years); 51% female]. T1 mapping was performed with a MOdified Look-Locker Inversion Recovery (MOLLI) sequence. T1 prognostic value in patients with pulmonary arterial hypertension was assessed using multivariate Cox proportional hazards regression analysis. RESULTS Patients with pulmonary artery hypertension had elevated T1 in the right ventricular (RV) insertion point (pulmonary hypertension patients: T1 = 1060 ± 90 ms; No pulmonary hypertension patients: T1 = 1020 ± 80 ms p < 0.001; healthy subjects T1 = 940 ± 50 ms p < 0.001) with no significant difference between the major pulmonary hypertension subtypes. The RV insertion point was the most successful T1 region for discriminating patients with pulmonary hypertension from healthy subjects (area under the curve = 0.863) however it could not accurately discriminate between patients with and without pulmonary hypertension (area under the curve = 0.654). T1 metrics did not contribute to prediction of overall mortality (septal: p = 0.552; RV insertion point: p = 0.688; left ventricular free wall: p = 0.258). Systolic interventricular septal angle was a significant predictor of T1 in patients with pulmonary hypertension (p < 0.001). CONCLUSIONS Elevated myocardial native T1 was found to a similar extent in pulmonary hypertension patient subgroups and is independently associated with increased interventricular septal angle. Native T1 mapping may not be of additive value in the diagnostic or prognostic evaluation of patients with pulmonary artery hypertension.
Collapse
Affiliation(s)
- Laura C. Saunders
- POLARIS, Academic Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Chris S. Johns
- POLARIS, Academic Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Neil J. Stewart
- POLARIS, Academic Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
- Division of Bioengineering and Bioinformatics, Graduate School of Information Science and Technology, Hokkaido University, Hokudai, Japan
| | - Charlotte J. E. Oram
- POLARIS, Academic Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - David A. Capener
- POLARIS, Academic Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Valentina O. Puntmann
- Institute for Experimental and Translational Cardio Vascular Imaging, University Hospital Frankfurt, Frankfurt, Germany
| | - Charlie A. Elliot
- Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
| | - Robin C. Condliffe
- Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
| | - David G. Kiely
- Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
- INSIGNEO, Institute for in-silico medicine, Sheffield, UK
| | - Martin J. Graves
- University of Cambridge School of Clinical Medicine, Cambridge University, Cambridge, UK
| | - Jim M. Wild
- POLARIS, Academic Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
- INSIGNEO, Institute for in-silico medicine, Sheffield, UK
| | - Andy J. Swift
- POLARIS, Academic Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
- INSIGNEO, Institute for in-silico medicine, Sheffield, UK
| |
Collapse
|
34
|
Puntmann VO, Valbuena S, Hinojar R, Petersen SE, Greenwood JP, Kramer CM, Kwong RY, McCann GP, Berry C, Nagel E. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification. J Cardiovasc Magn Reson 2018; 20:67. [PMID: 30231886 PMCID: PMC6147157 DOI: 10.1186/s12968-018-0484-5] [Citation(s) in RCA: 87] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Accepted: 08/05/2018] [Indexed: 02/07/2023] Open
Abstract
Cardiovascular disease remains a leading cause of morbidity and mortality globally. Changing natural history of the disease due to improved care of acute conditions and ageing population necessitates new strategies to tackle conditions which have more chronic and indolent course. These include an increased deployment of safe screening methods, life-long surveillance, and monitoring of both disease activity and tailored-treatment, by way of increasingly personalized medical care. Cardiovascular magnetic resonance (CMR) is a non-invasive, ionising radiation-free method, which can support a significant number of clinically relevant measurements and offers new opportunities to advance the state of art of diagnosis, prognosis and treatment. The objective of the SCMR Clinical Trial Taskforce was to summarizes the evidence to emphasize where currently CMR-guided clinical care can indeed translate into meaningful use and efficient deployment of resources results in meaningful and efficient use. The objective of the present initiative was to provide an appraisal of evidence on analytical validation, including the accuracy and precision, and clinical qualification of parameters in disease context, clarifying the strengths and weaknesses of the state of art, as well as the gaps in the current evidence This paper is complementary to the existing position papers on standardized acquisition and post-processing ensuring robustness and transferability for widespread use. Themed imaging-endpoint guidance on trial design to support drug-discovery or change in clinical practice (part II), will be presented in a follow-up paper in due course. As CMR continues to undergo rapid development, regular updates of the present recommendations are foreseen.
Collapse
Affiliation(s)
- Valentina O Puntmann
- Institute of Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt, Germany
- Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt, Germany
| | - Silvia Valbuena
- Department of Cardiology, University Hospital La Paz, Madrid, Germany
| | - Rocio Hinojar
- Department of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain
| | - Steffen E Petersen
- William Harvey Research Institute, Queen Mary University of London, Barts and the London NIHR Biomedical Research Centre at Barts, London, UK
| | - John P Greenwood
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
| | - Christopher M Kramer
- Department of Medicine (Cardiology) and Radiology, Cardiovascular Imaging Center, University of Virginia Health System, Charlottesville, Virginia, USA
| | - Raymond Y Kwong
- Cardiovascular Division, Department of Medicine, Brigham and Womens' Hospital, Boston, Massachusetts, USA
| | - Gerry P McCann
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
- the NIHR Leicester Cardiovascular Biomedical Centre, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK
| | - Colin Berry
- British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
- West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UK
| | - Eike Nagel
- Institute of Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt, Germany.
| |
Collapse
|
35
|
Winau L, Hinojar Baydes R, Braner A, Drott U, Burkhardt H, Sangle S, D'Cruz DP, Carr-White G, Marber M, Schnoes K, Arendt C, Klingel K, Vogl TJ, Zeiher AM, Nagel E, Puntmann VO. High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus. Ann Rheum Dis 2018; 77:1590-1598. [PMID: 30077990 DOI: 10.1136/annrheumdis-2018-213661] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Revised: 07/14/2018] [Accepted: 07/17/2018] [Indexed: 12/15/2022]
Abstract
BACKGROUND Cardiovascular (CV) involvement in patients with systemic lupus erythematosus (SLE) is presumably subclinical for the major part of its evolution. We evaluated the associations between high-sensitive troponin T (hs-TropT), a sensitive marker of myocardial injury, and CV involvement using cardiac magnetic resonance (CMR). METHODS AND RESULTS This is a two-centre (London and Frankfurt) CMR imaging study at 3.0 Tesla of consecutive 92 patients with SLE free of cardiac symptoms, undergoing screening for cardiac involvement. Venous samples were drawn and analysed post-hoc for cardiac biomarkers, including hs-TropT, high-sensitive C reactive protein and N-terminal pro brain natriuretic peptide. Compared with age-matched/gender-matched non-SLE controls (n=78), patients had significantly raised cardiac biomarker levels, native T1 and T2, aortic and ventricular stiffness, and reduced global longitudinal strain (p<0.01). In SLE, hs-TropT was significantly and independently associated with native T2, followed by the models including native T1 and aortic stiffness (Χ2 0.462, p<0.01). There were no relationships between hs-TropT and age, gender, CV risk factors, duration of systemic disease, cardiac structure or function, or late gadolinium enhancement. CONCLUSIONS Patients with SLE have a high prevalence of subclinical myocardial injury as demonstrated by raised high-sensitive troponin levels. CMR with T2 mapping reveals myocardial oedema as the strongest predictor of hs-TropT release, underscoring the inflammatory interstitial remodelling as the main mechanism of injury. Patients without active myocardial inflammation demonstrate diffuse interstitial remodelling and increased vascular stiffness. These findings substantiate the role of CMR in screening of subclinical cardiac involvement. TRIAL REGISTRATION NUMER NCT02407197; Results.
Collapse
Affiliation(s)
- Lea Winau
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Rocio Hinojar Baydes
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Cardiology, University Hospital Ramon y Cajal de Madrid, Madrid, Spain
| | - Axel Braner
- Department of Rheumatology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Ulrich Drott
- Department of Rheumatology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Harald Burkhardt
- Department of Rheumatology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Shirish Sangle
- The Louise Coote Lupus Unit, St Thomas' Hospital, London, UK
| | - David P D'Cruz
- The Louise Coote Lupus Unit, St Thomas' Hospital, London, UK
| | | | - Mike Marber
- Cardiovascular Sciences, King's College London, London, UK
| | - Katrin Schnoes
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Christophe Arendt
- Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Karin Klingel
- Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany
| | - Thomas J Vogl
- Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Andreas M Zeiher
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.,Department of Cardiology, St Thomas' Hospital, London, UK.,Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
36
|
Albrecht MH, De Cecco CN, Schoepf UJ, Spandorfer A, Eid M, De Santis D, Varga-Szemes A, van Assen M, von Knebel-Doeberitz PL, Tesche C, Puntmann VO, Nagel E, Vogl TJ, Nance JW. Dual-energy CT of the heart current and future status. Eur J Radiol 2018; 105:110-118. [PMID: 30017266 DOI: 10.1016/j.ejrad.2018.05.028] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 05/17/2018] [Accepted: 05/29/2018] [Indexed: 11/19/2022]
Abstract
Several applications utilizing dual-energy cardiac CT (DECT) have recently transitioned from the realm of research into clinical workflows. DECT acquisition techniques and subsequent post-processing can provide improved qualitative analysis, allow quantitative imaging, and have the potential to decrease requisite radiation and contrast material doses. Additionally, several experimental DECT techniques are pending further investigation and may improve the diagnostic accuracy of cardiac CT and/or provide evaluation of emerging imaging biomarkers in the future. This review article will summarize the major applications utilizing DECT in diagnosis of cardiovascular disease, including both the clinically used and investigational techniques examined to date.
Collapse
Affiliation(s)
- Moritz H Albrecht
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States; University Hospital Frankfurt, Department of Diagnostic and Interventional Radiology, Frankfurt, Germany.
| | - Carlo N De Cecco
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States.
| | - U Joseph Schoepf
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States.
| | - Adam Spandorfer
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States.
| | - Marwen Eid
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States.
| | - Domenico De Santis
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States; University of Rome "Sapienza", Department of Radiological Sciences, Oncological and Pathological Sciences, Latina, Italy.
| | - Akos Varga-Szemes
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States.
| | - Marly van Assen
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States; University Medical Center Groningen, Center for Medical Imaging, Department of Radiology, Groningen, The Netherlands.
| | - Philipp L von Knebel-Doeberitz
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States.
| | - Christian Tesche
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States; Heart Center Munich-Bogenhausen, Department of Cardiology and Intensive Care Medicine, Munich, Germany.
| | - Valentina O Puntmann
- University Hospital Frankfurt, Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Frankfurt, Germany.
| | - Eike Nagel
- University Hospital Frankfurt, Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Frankfurt, Germany.
| | - Thomas J Vogl
- University Hospital Frankfurt, Department of Diagnostic and Interventional Radiology, Frankfurt, Germany.
| | - John W Nance
- Medical University of South Carolina, Department of Radiology and Radiological Science, Division of Cardiovascular Imaging, Charleston, SC, United States.
| |
Collapse
|
37
|
Affiliation(s)
- Valentina O. Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt, Germany
- Department of Cardiology, Division of Internal Medicine III, Goethe University Hospital Frankfurt, Frankfurt, Germany
| | - Andreas M. Zeiher
- Department of Cardiology, Division of Internal Medicine III, Goethe University Hospital Frankfurt, Frankfurt, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
38
|
Pathan F, Puntmann VO, Nagel E. Role of Cardiac Magnetic Resonance in Heart Failure with Preserved Ejection Fraction. Curr Cardiovasc Imaging Rep 2018. [DOI: 10.1007/s12410-018-9450-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
39
|
Selvadurai BSN, Puntmann VO, Bluemke DA, Ferrari VA, Friedrich MG, Kramer CM, Kwong RY, Lombardi M, Prasad SK, Rademakers FE, Young AA, Kim RJ, Nagel E. Definition of Left Ventricular Segments for Cardiac Magnetic Resonance Imaging. JACC Cardiovasc Imaging 2017; 11:926-928. [PMID: 29248663 DOI: 10.1016/j.jcmg.2017.09.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Revised: 09/15/2017] [Accepted: 09/18/2017] [Indexed: 10/18/2022]
|
40
|
Child N, Suna G, Dabir D, Yap ML, Rogers T, Kathirgamanathan M, Arroyo-Ucar E, Hinojar R, Mahmoud I, Young C, Wendler O, Mayr M, Sandhu B, Morton G, Muhly-Reinholz M, Dimmeler S, Nagel E, Puntmann VO. Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction. Eur Heart J Cardiovasc Imaging 2017; 19:768-776. [DOI: 10.1093/ehjci/jex309] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2017] [Accepted: 10/31/2017] [Indexed: 11/13/2022] Open
Affiliation(s)
- Nicholas Child
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
- Cardiovascular Division, King’s College London, The Rayne Institute. St Thomas' Hospital, Westminster Bridge Road, London SE5 9RS, UK
| | - Gonca Suna
- Cardiovascular Division, King’s College London, The Rayne Institute. St Thomas' Hospital, Westminster Bridge Road, London SE5 9RS, UK
- Department of Cardiology, King’s College Hospital NHS Trust, Denmark Hill, London, UK
| | - Darius Dabir
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
- Department of Radiology, University of Bonn, Regina-Pacis-Weg 3, Bonn, Germany
| | - May-Lin Yap
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
| | - Toby Rogers
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
- Department of Cardiology, King’s College Hospital NHS Trust, Denmark Hill, London, UK
| | - Misha Kathirgamanathan
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
| | - Eduardo Arroyo-Ucar
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
- Department of Cardiology, University of Hospital, Paseo de la Castellana, La Paz, Madrid, Spain
| | - Rocio Hinojar
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
| | - Islam Mahmoud
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
| | - Christopher Young
- Department of Cardiothoracic Surgery, Queen Alexandra Hospital, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
| | - Olaf Wendler
- Department of Cardiothoracic Surgery, King’s College Hospital, Denmark Hill, London, UK
| | - Manuel Mayr
- Cardiovascular Division, King’s College London, The Rayne Institute. St Thomas' Hospital, Westminster Bridge Road, London SE5 9RS, UK
| | - Banher Sandhu
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
| | - Geraint Morton
- Department of Cardiology, Portsmouth Hospitals NHS Trust, Southwick Hill Road, Portsmouth, UK
| | - Marion Muhly-Reinholz
- Institute for Cardiovascular Regeneration, University of Frankfurt, German Centre of Cardiovascular Research, (DZHK), Theodor-Stern-Kai 7, Frankfurt, Germany
| | - Stefanie Dimmeler
- Institute for Cardiovascular Regeneration, University of Frankfurt, German Centre of Cardiovascular Research, (DZHK), Theodor-Stern-Kai 7, Frankfurt, Germany
| | - Eike Nagel
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
- Institute of Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt, German Centre of Cardiovascular Research, (DZHK), Theodor-Stern-Kai 7, Frankfurt, Germany
| | - Valentina O Puntmann
- Department of Cardiology, Guys and St Thomas’ NHS Trust, Westminster Bridge Road, London, UK
- Institute of Experimental and Translational Cardiovascular Imaging, Goethe University Hospital Frankfurt, German Centre of Cardiovascular Research, (DZHK), Theodor-Stern-Kai 7, Frankfurt, Germany
- Department of Cardiology, Goethe University Hospital Frankfurt, German Centre of Cardiovascular Research, (DZHK), Theodor-Stern-Kai 7, Frankfurt, Germany
| |
Collapse
|
41
|
D’Angelo T, Grigoratos C, Mazziotti S, Bratis K, Pathan F, Blandino A, Elen E, Puntmann VO, Nagel E. High-throughput gadobutrol-enhanced CMR: a time and dose optimization study. J Cardiovasc Magn Reson 2017; 19:83. [PMID: 29110679 PMCID: PMC5674223 DOI: 10.1186/s12968-017-0400-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 10/16/2017] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Reducing time and contrast agent doses are important goals to provide cost-efficient cardiovascular magnetic resonance (CMR) imaging. Limited information is available regarding the feasibility of evaluating left ventricular (LV) function after gadobutrol injection as well as defining the lowest dose for high quality scar imaging. We sought to evaluate both aspects separately and systematically to provide an optimized protocol for contrast-enhanced CMR (CE-CMR) using gadobutrol. METHODS This is a prospective, randomized, single-blind cross-over study performed in two different populations. The first population consisted of 30 patients with general indications for a rest CE-CMR who underwent cine-imaging before and immediately after intravenous administration of 0.1 mmol/kg body-weight of gadobutrol. Quantitative assessment of LV volumes and function was performed by the same reader in a randomized and blinded fashion. The second population was composed of 30 patients with indication to late gadolinium enhancement (LGE) imaging, which was performed twice at different gadobutrol doses (0.1 mmol/kg vs. 0.2 mmol/kg) and at different time delays (5 and 10 min vs. 5, 10, 15 and 20 min), within a maximal interval of 21 days. LGE images were analysed qualitatively (contrast-to-noise ratio) and quantitatively (LGE%-of-mass). RESULTS Excellent correlation between pre- and post-contrast cine-imaging was found, with no difference of LV stroke volume and ejection fraction (p = 0.538 and p = 0.095, respectively). End-diastolic-volume and end-systolic-volume were measured significantly larger after contrast injection (p = 0.008 and p = 0.001, respectively), with a mean difference of 3.7 ml and 2.9 ml, respectively. LGE imaging resulted in optimal contrast-to-noise ratios 10 min post-injection for a gadobutrol dose of 0.1 mmol/kg body-weight and 20 min for a dose of 0.2 mmol/kg body-weight. At these time points LGE quantification did not significantly differ (0.1 mmol/kg: 11% (16.4); 0.2 mmol/kg: 12% (14.5); p = 0.059), showing excellent correlation (ICC = 0.957; p < 0.001). CONCLUSION A standardized CE-CMR rest protocol giving a dose of 0.1 mmol/kg of gadobutrol before cine-imaging and performing LGE 10 min after injection represents a fast low-dose protocol without significant loss of information in comparison to a longer protocol with cine-imaging before contrast injection and a higher dose of gadobutrol. This approach allows to reduce examination time and costs as well as minimize contrast-agent exposure.
Collapse
Affiliation(s)
- Tommaso D’Angelo
- Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Via Consolare Valeria, 1, 98100 Messina, Italy
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern- Kai 7, Frankfurt am Main, Germany
| | - Chrysanthos Grigoratos
- G. Monasterio CNR-Tuscany Foundation, Pisa, Italy
- Department of Cardiovascular Imaging, King’s College London, Lambeth Wing, St. Thomas’ Hospital, London, UK
| | - Silvio Mazziotti
- Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Via Consolare Valeria, 1, 98100 Messina, Italy
| | - Konstantinos Bratis
- Department of Cardiovascular Imaging, King’s College London, Lambeth Wing, St. Thomas’ Hospital, London, UK
| | - Faraz Pathan
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern- Kai 7, Frankfurt am Main, Germany
- Department of Cardiology, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
| | - Alfredo Blandino
- Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Via Consolare Valeria, 1, 98100 Messina, Italy
| | - Elen Elen
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern- Kai 7, Frankfurt am Main, Germany
- Department of Cardiology, National Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta, Indonesia
| | - Valentina O. Puntmann
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern- Kai 7, Frankfurt am Main, Germany
- Department of Cardiovascular Imaging, King’s College London, Lambeth Wing, St. Thomas’ Hospital, London, UK
- Department of Cardiology, University Hospital Frankfurt, DZHK Rhein-Main, Theodor-Stern- Kai 7, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern- Kai 7, Frankfurt am Main, Germany
- Department of Cardiovascular Imaging, King’s College London, Lambeth Wing, St. Thomas’ Hospital, London, UK
- Department of Cardiology, University Hospital Frankfurt, DZHK Rhein-Main, Theodor-Stern- Kai 7, Frankfurt am Main, Germany
| |
Collapse
|
42
|
Abstract
Cardiovascular magnetic resonance provides insights into myocardial structure and function noninvasively, with high diagnostic accuracy and without ionizing radiation. Myocardial tissue characterization in particular gives cardiovascular magnetic resonance a prime role among all the noninvasive cardiovascular investigations. Late gadolinium enhancement imaging is an established method for visualizing replacement scar, providing diagnostic and prognostic information in a variety of cardiac conditions. Late gadolinium enhancement, however, relies on the regional segregation of tissue characteristics to generate the imaging contrast. Thus, myocardial pathology that is diffuse in nature and affecting the myocardium in a rather uniform and global distribution is not well visualized with late gadolinium enhancement. Examples include diffuse myocardial inflammation, fibrosis, hypertrophy, and infiltration. T1 mapping is a novel technique allowing to diagnose these diffuse conditions by measurement of T1 values, which directly correspond to variation in intrinsic myocardial tissue properties. In addition to providing clinically meaningful indices, T1-mapping measurements also allow for an estimation of extracellular space by calculation of extracellular volume fraction. Multiple lines of evidence suggest a central role for T1 mapping in detection of diffuse myocardial disease in early disease stages and complements late gadolinium enhancement in visualization of the regional changes in common advanced myocardial disease. As a quantifiable measure, it may allow grading of disease activity, monitoring progress, and guiding treatment, potentially as a fast contrast-free clinical application. We present an overview of clinically relevant technical aspects of acquisition and processing, and the current state of art and evidence, supporting its clinical use.
Collapse
Affiliation(s)
- Valentina O Puntmann
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging (V.O.P., E.P., E.N.) and Department of Cardiology (V.O.P., E.N.), Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, Ankara University School of Medicine, Ankara, Turkey (E.P.); and University of Minnesota and VA Medical Centre, Minneapolis (Y.C.)
| | - Elif Peker
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging (V.O.P., E.P., E.N.) and Department of Cardiology (V.O.P., E.N.), Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, Ankara University School of Medicine, Ankara, Turkey (E.P.); and University of Minnesota and VA Medical Centre, Minneapolis (Y.C.)
| | - Y Chandrashekhar
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging (V.O.P., E.P., E.N.) and Department of Cardiology (V.O.P., E.N.), Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, Ankara University School of Medicine, Ankara, Turkey (E.P.); and University of Minnesota and VA Medical Centre, Minneapolis (Y.C.)
| | - Eike Nagel
- From the Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging (V.O.P., E.P., E.N.) and Department of Cardiology (V.O.P., E.N.), Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, Ankara University School of Medicine, Ankara, Turkey (E.P.); and University of Minnesota and VA Medical Centre, Minneapolis (Y.C.).
| |
Collapse
|
43
|
Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis. Radiology 2017; 285:63-72. [PMID: 28448233 DOI: 10.1148/radiol.2017162732] [Citation(s) in RCA: 109] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Purpose To determine whether quantitative tissue characterization with T1 and T2 mapping supports recognition of myocardial involvement in patients with systemic sarcoidosis. Materials and Methods Fifty-three consecutive patients with a biopsy-proven extracardiac diagnosis of systemic sarcoidosis (21 men; median age, 45 years; interquartile range, 22 years) and 36 normotensive previously healthy control subjects (14 men; median age, 43 years; interquartile range, 18 years) underwent cardiovascular magnetic resonance imaging, which was performed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping. A follow-up substudy was performed in 40 patients (mean follow-up interval, 144 days ± 35 [standard deviation]); of these 40 patients, 18 underwent anti-inflammatory treatment for systemic symptoms. Binary logistic regression and receiver operating characteristic curve analyses were used to assess discrimination between health and disease; Wilcoxon signed rank test was used to assess the effect of treatment. Results When compared with control subjects, patients had higher ventricular volume, higher myocardial native T1 and T2, and lower longitudinal strain and ejection fraction (P < .05 for all). Myocardial native T1 and T2 had higher discriminatory accuracy (area under the receiver operating characteristic curve [AUC]: 0.96 and 0.89, respectively) for separation between control subjects and patients when compared with the standard diagnostic criteria (AUC < 0.67). Native T1 was the independent discriminator between health and disease (specificity, 90%; sensitivity, 96%; accuracy, 94%). There was a significant reduction of native T1 and T2 in the patients who underwent treatment (z score: -3.72 and -2.88; P < .01) but not in the patients who did not (z score, -1.42 and -1.38; P > .15). Conclusion Quantitative myocardial tissue characterization with T1 and T2 mapping may enable noninvasive recognition of cardiac involvement and activity of myocardial inflammation in patients with systemic sarcoidosis. Future studies will be performed to confirm their role in risk stratification and guidance of clinical management. © RSNA, 2017 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Valentina O Puntmann
- From the Department of Cardiology, Guy's and St Thomas' NHS Trust, London, England (V.O.P., A.I., R.H., L.F., G.C., E.N.); Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany (V.O.P., E.N.); Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany (V.O.P.); Department of Cardiovascular Imaging, King's College London, St. Thomas' Hospital, London, England (V.O.P.); Ramón y Cajal University Hospital, University of Alcalá, Madrid, Spain (R.H.); and King's College Hospital NHS Trust, Denmark Hill, London, England (G.C.)
| | - Alexander Isted
- From the Department of Cardiology, Guy's and St Thomas' NHS Trust, London, England (V.O.P., A.I., R.H., L.F., G.C., E.N.); Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany (V.O.P., E.N.); Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany (V.O.P.); Department of Cardiovascular Imaging, King's College London, St. Thomas' Hospital, London, England (V.O.P.); Ramón y Cajal University Hospital, University of Alcalá, Madrid, Spain (R.H.); and King's College Hospital NHS Trust, Denmark Hill, London, England (G.C.)
| | - Rocio Hinojar
- From the Department of Cardiology, Guy's and St Thomas' NHS Trust, London, England (V.O.P., A.I., R.H., L.F., G.C., E.N.); Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany (V.O.P., E.N.); Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany (V.O.P.); Department of Cardiovascular Imaging, King's College London, St. Thomas' Hospital, London, England (V.O.P.); Ramón y Cajal University Hospital, University of Alcalá, Madrid, Spain (R.H.); and King's College Hospital NHS Trust, Denmark Hill, London, England (G.C.)
| | - Lucy Foote
- From the Department of Cardiology, Guy's and St Thomas' NHS Trust, London, England (V.O.P., A.I., R.H., L.F., G.C., E.N.); Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany (V.O.P., E.N.); Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany (V.O.P.); Department of Cardiovascular Imaging, King's College London, St. Thomas' Hospital, London, England (V.O.P.); Ramón y Cajal University Hospital, University of Alcalá, Madrid, Spain (R.H.); and King's College Hospital NHS Trust, Denmark Hill, London, England (G.C.)
| | - Gerald Carr-White
- From the Department of Cardiology, Guy's and St Thomas' NHS Trust, London, England (V.O.P., A.I., R.H., L.F., G.C., E.N.); Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany (V.O.P., E.N.); Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany (V.O.P.); Department of Cardiovascular Imaging, King's College London, St. Thomas' Hospital, London, England (V.O.P.); Ramón y Cajal University Hospital, University of Alcalá, Madrid, Spain (R.H.); and King's College Hospital NHS Trust, Denmark Hill, London, England (G.C.)
| | - Eike Nagel
- From the Department of Cardiology, Guy's and St Thomas' NHS Trust, London, England (V.O.P., A.I., R.H., L.F., G.C., E.N.); Institute of Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany (V.O.P., E.N.); Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany (V.O.P.); Department of Cardiovascular Imaging, King's College London, St. Thomas' Hospital, London, England (V.O.P.); Ramón y Cajal University Hospital, University of Alcalá, Madrid, Spain (R.H.); and King's College Hospital NHS Trust, Denmark Hill, London, England (G.C.)
| |
Collapse
|
44
|
Hinojar R, Foote L, Sangle S, Marber M, Mayr M, Carr-White G, D'Cruz D, Nagel E, Puntmann VO. Native T1 and T2 mapping by CMR in lupus myocarditis: Disease recognition and response to treatment. Int J Cardiol 2016; 222:717-726. [DOI: 10.1016/j.ijcard.2016.07.182] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Accepted: 07/28/2016] [Indexed: 11/16/2022]
|
45
|
Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S, Hinojar R, Doltra A, Varma N, Child N, Rogers T, Suna G, Arroyo Ucar E, Goodman B, Khan S, Dabir D, Herrmann E, Zeiher AM, Nagel E. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. JACC Cardiovasc Imaging 2016; 9:40-50. [PMID: 26762873 DOI: 10.1016/j.jcmg.2015.12.001] [Citation(s) in RCA: 334] [Impact Index Per Article: 41.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Revised: 12/01/2015] [Accepted: 12/01/2015] [Indexed: 11/17/2022]
Abstract
OBJECTIVES The study sought to examine prognostic relevance of T1 mapping parameters (based on a T1 mapping method) in nonischemic dilated cardiomyopathy (NIDCM) and compare them with conventional markers of adverse outcome. BACKGROUND NIDCM is a recognized cause of poor clinical outcome. NIDCM is characterized by intrinsic myocardial remodeling due to complex pathophysiological processes affecting myocardium diffusely. Lack of accurate and noninvasive characterization of diffuse myocardial disease limits recognition of early cardiomyopathy and effective clinical management in NIDCM. Cardiac magnetic resonance (CMR) supports detection of diffuse myocardial disease by T1 mapping. METHODS This is a prospective observational multicenter longitudinal study in 637 consecutive patients with dilated NIDCM (mean age 50 years [interquartile range: 37 to 76 years]; 395 males [62%]) undergoing CMR with T1 mapping and late gadolinium enhancement (LGE) at 1.5-T and 3.0-T. The primary endpoint was all-cause mortality. A composite of heart failure (HF) mortality and hospitalization was a secondary endpoint. RESULTS During a median follow-up period of 22 months (interquartile range: 19 to 25 months), we observed a total of 28 deaths (22 cardiac) and 68 composite HF events. T1 mapping indices (native T1 and extracellular volume fraction), as well as the presence and extent of LGE, were predictive of all-cause mortality and HF endpoint (p < 0.001 for all). In multivariable analyses, native T1 was the sole independent predictor of all-cause and HF composite endpoints (hazard ratio: 1.1; 95% confidence interval: 1.06 to 1.15; hazard ratio: 1.1; 95% confidence interval: 1.05 to 1.1; p < 0.001 for both), followed by the models including the extent of LGE and right ventricular ejection fraction, respectively. CONCLUSIONS Noninvasive measures of diffuse myocardial disease by T1 mapping are significantly predictive of all-cause mortality and HF events in NIDCM. We provide a basis for a novel algorithm of risk stratification in NIDCM using a complementary assessment of diffuse and regional disease by T1 mapping and LGE, respectively.
Collapse
Affiliation(s)
- Valentina O Puntmann
- Guys and St Thomas' NHS Trust, London, England; King's College Hospital NHS Trust, London, England; Department of Cardiology, University Hospital Frankfurt, Frankfurt-am Main, Germany; Department of Cardiac Imaging, King's College London, London, England.
| | - Gerry Carr-White
- Guys and St Thomas' NHS Trust, London, England; King's College Hospital NHS Trust, London, England
| | | | | | - Rolf Gebker
- German Heart Institute Berlin, Berlin, Germany
| | | | - Rocio Hinojar
- Guys and St Thomas' NHS Trust, London, England; Department of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain
| | | | - Niharika Varma
- Guys and St Thomas' NHS Trust, London, England; Department of Cardiac Imaging, King's College London, London, England
| | - Nicholas Child
- Guys and St Thomas' NHS Trust, London, England; Department of Cardiac Imaging, King's College London, London, England
| | - Toby Rogers
- King's College Hospital NHS Trust, London, England; Department of Cardiac Imaging, King's College London, London, England
| | - Gonca Suna
- King's College Hospital NHS Trust, London, England; Cardiovascular Division, King's College London, London, England
| | | | - Ben Goodman
- Guys and St Thomas' NHS Trust, London, England
| | - Sitara Khan
- King's College Hospital NHS Trust, London, England; Cardiovascular Division, King's College London, London, England
| | - Darius Dabir
- Guys and St Thomas' NHS Trust, London, England; Department of Radiology, University of Bonn, Bonn, Germany
| | - Eva Herrmann
- Institute of Biostatistics and Mathematical Modelling at Goethe University Frankfurt; Frankfurt am Main, Germany
| | - Andreas M Zeiher
- Department of Cardiology, University Hospital Frankfurt, Frankfurt-am Main, Germany
| | - Eike Nagel
- Guys and St Thomas' NHS Trust, London, England; King's College Hospital NHS Trust, London, England; Department of Cardiology, University Hospital Frankfurt, Frankfurt-am Main, Germany; Department of Cardiac Imaging, King's College London, London, England; Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
46
|
Puntmann VO, Nagel E. T1 and T2 Mapping in Nonischemic Cardiomyopathies and Agreement With Endomyocardial Biopsy. J Am Coll Cardiol 2016; 68:1923-1924. [DOI: 10.1016/j.jacc.2016.06.075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 06/07/2016] [Indexed: 10/20/2022]
|
47
|
Gerster M, Peker E, Nagel E, Puntmann VO. Deciphering cardiac involvement in systemic inflammatory diseases: noninvasive tissue characterisation using cardiac magnetic resonance is key to improved patients’ care. Expert Rev Cardiovasc Ther 2016; 14:1283-1295. [DOI: 10.1080/14779072.2016.1226130] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
48
|
Hinojar R, Nagel E, Puntmann VO. Advances in Cardiovascular MRI using Quantitative Tissue Characterisation Techniques: Focus on Myocarditis. Eur Cardiol 2016; 11:20-24. [PMID: 30310443 DOI: 10.15420/ecr.2016:18:2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Tissue characterisation capabilities are continuing to evolve and proving to be valuable in the non-invasive diagnosis of clinically-heterogeneous manifestations of myocarditis. The authors investigate how cardiovascular magnetic resonance imaging offers an increasingly reliable alternative to invasive biopsy for clinically-stable patients, and how this tool - with further longitudinal study - will improve the overall understanding of the natural course of myocarditis.
Collapse
Affiliation(s)
- Rocio Hinojar
- Institute for experimental and translational cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt, Germany.,Department of Cardiology, University Hospital Ramón y Cajal, Alcala University, Madrid, Spain
| | - Eike Nagel
- Institute for experimental and translational cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt, Germany
| | - Valentina O Puntmann
- Institute for experimental and translational cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt, Germany.,Department of Cardiology, Division of Internal Medicine III, Goethe University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
49
|
Dweck MR, Puntmann VO, Vesey AT, Fayad ZA, Nagel E. MR Imaging of Coronary Arteries and Plaques. JACC Cardiovasc Imaging 2016; 9:306-16. [DOI: 10.1016/j.jcmg.2015.12.003] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 11/25/2015] [Accepted: 12/03/2015] [Indexed: 01/13/2023]
|
50
|
Valbuena-López S, Hinojar R, Puntmann VO. Cardiovascular Magnetic Resonance in Cardiology Practice: A Concise Guide to Image Acquisition and Clinical Interpretation. ACTA ACUST UNITED AC 2016; 69:202-10. [DOI: 10.1016/j.rec.2015.11.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 11/10/2015] [Indexed: 10/22/2022]
|